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ABSTRACT

Park, Jonghyuck. Ph.D., Purdue University, December 2014. Acrolein as a Novel
Therapeutic Target for Spinal Cord Injury Induced Neuropathic Pain. Major Professor:
Riyi Shi, M.D., Ph.D.
Despite years of research, post-spinal cord injury (SCI) chronic neuropathic pain remains
refractory to treatment and drastically impairs quality of life for SCI victims beyond
paralysis. Although inflammation and free radicals contribute to neuropathic pain in SCI,
the mechanism is not completely clear. We have recently demonstrated that acrolein, a
product and catalyst of lipid peroxidation, induces a vicious cycle of oxidative stress,
amplifying its effects and perpetuating oxidative stress and inflammation. In the current
study, we have confirmed that acrolein is elevated significantly at least two weeks postSCI which coincides with the emergence of hyperalgesia (mechanical, cold and
thermal). Furthermore, anti-acrolein treatment hydalazine can reverse pain behavior.
Consistent with this, acrolein is a known ligand that directly excites transient receptor
potential ankyrin 1 receptor (TRPA1) in DRG nociceptive neurons to transmit pain
sensation. In addition, we have observed a significant increase of monocyte
chemoattractant protein-1 (MCP1), a pro-inflammatory chemokine that is also known be
increased upon acrolein stimulation and capable of sensitizing TRPA1 following SCI.
Similarly, we observed a heightened excitatory response of DRG sensory neurons to
current stimulation in the presence of acrolein, indicating an enhanced sensitivity of DRG
cells to acrolein post SCI. In summary, acrolein may play an important role in the post
SCI hyperalgesia through greater direct binding to TRPA1 and enhanced sensitivity of
DRG to acrolein via MCP1-mediated pathway
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CHAPTER 1. INTRODUCTION

1.1

Introduction of Spinal Cord Injury
According to the National Spinal Cord Injury Statistical Center, there are

approximately 400,000 spinal cord injured patients in the United States with over 14,000
new injuries occurring each year. Traumatic spinal cord injury (SCI) could result in
irreversible never injury which leads to both motor and sensory malfunction. In addition
to the motor and sensory dysfunction, SCI patients can also suffer from various levels of
neuropathic pain, bladder reflexive dysfunction, urinary tract infection, renal malfunction,
loss of respiratory function, loss of sexual function, pneumonia, deep vein thrombosis,
pulmonary embolism, and septicemia. These SCI-induced disorders have significantly
negative effects on their quality of life. In addition, SCI results in significant financial
impact. Based on data from the National Spinal Cord Injury Statistical Center, the
estimated lifetime costs for a 25 years old tetraplegia patient is over $3 millions.
Despite years of study to improve the functional recovery and the quality of life,
lack of effective therapeutic targets result in a frustrating condition to treat. High doses of
methylprednisolone have been using as a standard care for SCI clinical trials because of
its antioxidant properties (Bracken et al., 1997; Bracken et al., 1998; Bracken and
Holford, 2002). However, recent clinical trials have failed to improve functional recovery
after SCI with methylprednisolone treatment. Based on research, this treatment could
lead to respiratory tract infection, urinary tract infection, pulmonary embolism, and
gastrointestinal problems (George, 1995; Matsumoto et al., 2001; Lee et al., 2007;
Suberviola et al., 2008b). Even though treatment with methylprednisolone may not be
effect way to improve SCI patients’ symptoms, these clinical applications demonstrated

2
that attenuating oxidative stress, as a one of the therapeutic strategies, could be a effective
way to improve the motor and sensory dysfunction following SCI.

1.2

The Role of Oxidative Stress after SCI
One of the critical features of SCI pathophysiology is the secondary cascade events

after primary traumatic SCI, which occur in the hours, days, and weeks including
ischemia/reperfusion injury, inflammation, oxidative stress, and glutamate excitotoxicity
(Braughler and Hall, 1989b; Juurlink and Paterson, 1998b; Hall and Springer, 2004). The
secondary cascade events result in spreading of additional damage throughout the spinal
cord and contributing to the tissue degeneration and functional loss (Hall and Springer,
2004; Huang and Huang, 2006).
As a key factor of secondary cascade events, oxidative stress plays a critical role in
mediating motor and sensory dysfunction after SCI. In addition, oxidative stress has been
implicated in various neurodegenerative diseases (Hall, 1989; Hall and Braughler, 1993a;
Smith et al., 1999; Seiler, 2000). Traumatic mechanical SCI injury to the membrane
induces the disruption the intracellular calcium and sodium rise, and potassium falls
which contribute to depolarization leading to intracellular level of calcium and sodium
increase more. Furthermore, increase level of calcium could result in mitochondria injury
and an increase in production and release of reactive oxygen species (ROS) (Hall, 1996;
Xiong et al., 2007).
Traumatic primary SCI induces blood supply disruption which results in ischemiareperfusion secondary injury. Shortage of oxygen and glucose may lead to impaired ATP
production, mitochondrial damage, and generation and leakage of ROS from
mitochondria (Braughler and Hall, 1989a; Hall and Braughler, 1993b). The generation of
xanthine oxidase has been found to produce superoxide after ischemia-reperfusion
damage (Braughler and Hall, 1989a; Hall, 1996; Juurlink and Paterson, 1998a; Kumar et
al., 2004). In addition, recruitment of neutrophils to the tissue damage site and their
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activations results in the increase in generation of ROS (Braughler and Hall, 1989a;
Lewen et al., 2000).
The central nerve system (CNS) is especially very sensitive to oxidative stress
because of its unique properties. Particularly, the CNS, compared to the other tissue,
contains large proportion of phospholipids membrane and poly unsaturated fatty acids,
which are specifically vulnerable to peroxidation (Hall and Braughler, 1993b; Hall, 1996;
Halliwell and Gutteridge, 1999). Furthermore, compared to other types of cells, there are
a number of mitochondria that could be a target and source of ROS. Under the high level
of oxidative stress, the endogenous antioxidants such as glutathione, vitamin E, and
ascorbic acid could be overwhelmed because the level of antioxidants may not be
compensated due to rapid consumption. Even though many of research groups have been
demonstrated that oxidative stress plays an important role in the pathogenesis after SCI,
clinical trials with free radical scavengers have failed to promote functional recovery
after traumatic SCI (George et al., 1995; Bracken et al., 1997; Bracken et al., 1998;
Suberviola et al., 2008a). Therefore, we need to understand the mechanisms of oxidative
stress and investigate the novel and effective therapeutic targets for SCI.
In addition to SCI, many of byproducts of oxidative stress have been implicated in
numerous neurodegenerative diseases (Liu and Ji; Yowtak et al.; Hensley et al., 2000;
Vincent et al., 2002; Naoi et al., 2005; Schwartz et al., 2008). The research for
byproducts of oxidative stress-mediated neuronal diseases has been an intense area to
prevent and slow down the development of various neurodegenerative diseases. However,
clinical trials with free radical scavengers have not produced meaningful outcome similar
to SCI. In this sense, this study could have critical applications for not only SCI patients
but also for other neurodegenerative diseases.
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1.3

The Origin of Acrolein and Role of Acrolein in Spinal Cord Injury
Acrolein is a highly reactive α,β-unsaturated aldehyde (Figure 1.) that is an

environmental pollutant and byproduct of lipid peroxidation (LPO) after traumatic injury
to spinal cord (Uchida, 1999a; Lovell et al., 2000; O'Brien et al., 2005). Acrolein can
originate via endogenous pathway from LPO of poly unsaturated fatty acid in cell
membrane, carbohydrates and amino acids. In addition, generation of acrolein occurs
through exogenously such as incomplete combustion of organics, manufacturing
processes, and cigarette smoke (Witz, 1989; Esterbauer et al., 1991a; Ghilarducci and
Tjeerdema, 1995; Kirkham et al., 2003; Hamann et al., 2008b).

Figure1. Structure of Acrolein
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In addition, because acrolein can act as byproducts and inducers of LPO, it has
been implicated in many neurological diseases (Shi et al.; Horton et al., 1999; Lovell et
al., 2000; Waxman, 2001; Luo and Shi, 2004; Luo et al., 2005a; Liu-Snyder et al., 2006b;
Due et al., 2014). Acrolein has been shown to be the most reactive and abundant
electrophile byproducts of LPO compared to much studied ROS. In addition, it can
directly bind to proteins, DNA, and endogenous antioxidant glutathione (GSH) and reacts
with GSH 100-150 times faster than another type of LPO byproducts such as 4hydroxynonenal (4-HNE) (Witz, 1989; Esterbauer et al., 1991a; Hall and Braughler,
1993b; Ghilarducci and Tjeerdema, 1995; Uchida et al., 1998; Halliwell and Gutteridge,
1999; Uchida, 1999b). Furthermore, half life of acrolein is significantly longer than that
of other transient ROS. Acrolein-protein and acrolein-GSH adducts also have much
longer half-lives than those of free acrolein and significantly reactive (Adams and
Klaidman, 1993; Burcham et al., 2004; Kaminskas et al., 2004b). In addition, acrolein
can react with the thiol group of cysteine residue, the ε-amino group of lysine and
histidine residues to generate reactive carbonyl-retaining adducts through the Michael
addition (Esterbauer et al., 1991a; Burcham et al., 2004; Kaminskas et al., 2004a;
Burcham and Pyke, 2006). Particularly, binding between acrolein and cystein via Michael
addition is reversible so that acrolein can break from acrolein-cystein adduct and allow it
to continue to react with other proteins. Acrolein can also bind to necleophilic DNA
bases to generate exocyclic adducts (Kehrer and Biswal, 2000a). Through this pathway,
acrolein can induce vicious cycle of oxidative stress and amplify its effect to many
biochemical processes (Figure 2).
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Figure2. Vicious Cycle of Oxidative Stress by Acrolein after Traumatic SCI.
1.4

Acrolein Detection Techniques
Because of reactive and volatility nature of acrolein, the detection of free acrolein is

technically challenging. In addition, acrolein is able to undergo spontaneous
polymerization, reduction, and oxidation because there are carbonyl and vinyl functional
groups on the molecule (Shi et al., 2011). In this sense, based on the current researches
and understating of characteristics of acrolein, it is reasonable to anticipate that majority
of endogenous acrolein would exist in acrolein-protein adducts or be metabolized by
endogenous antioxidants such as GSH and vitamin E.
Detecting acrolein-lysine adduct level by using immunoblotting methods has been
using in many rat SCI model (Uchida, 1999a; Hamann et al., 2008b; Hamann and Shi,
2009; Park et al., 2013) (Figure 3). By using these techniques, many researchers could
quantify the in vivo acrolein adducts level directly at the tissue of interest. In addition,
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with the acrolein standard, actual in vivo acrolein level could be estimated. Although
immunoblotting methods are very sensitive for in vivo acrolein level detection, using
anti-acrolein antibodies to detect acrolein-lysine adduct only represent a portion of the
total generated acrolein, which could always underestimate the actual acrolein level in the
tissue. In addition, acrolein normally reacts with endogenous antioxidant GSH first,
which results in a relative small amount of acrolein would bind to protein in normal
condition of cell. Under this condition, immunoblotting methods could overlook the in
vivo level of acrolein. Lastly, these methods are highly invasive because animals should
be sacrificed to collect tissues which significantly limit their applications for the clinical
trial. Therefore, a non-invasive method for detecting acrolein or acrolein metabolites
would be effective for the investigation of acrolein-mediated neurodegenerative diseases
and for the clinical application.
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Figure 3. Detection of Acrolein-lysine Level through Immunoblotting Method.
Top: artificially acrolein standard were prepared with different concentrations of acroelin.
The monoclonal anti-acrolein antibody was used for acrolein standard samples. Bottom:
based on the optical density of prepared acrolein samples, sample standard curve was
calculated and this standard curve could be used for acrolein level quantification.
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Non-invasive acrolein level measurement through acrolein metabolite in urine
quantification has been reported (Zheng et al.; Lovell et al., 2001b; Abraham et al., 2011;
Zheng et al., 2013) (Figure 4). Rather than invasive acrolein measuring via
immunoblotting, this method was considered to be an indirect indicator of the in vivo
acrolein level. In addition, detecting acrolein metabolite through collecting urine makes it
particularly promise for the clinical applications. Specifically, 3-hydroxypropyl
mercapturic acid (3-HPMA) has been selected as a major acrolein metabolite in urine
(Park et al., 2000; Yan et al., 2010). Chemically, 3-HPMA is very stable and be kept for
months in the freezer without sample deterioration. Furthermore, binding ratio between
acrolein and GSH is 1:1, which indicates that 3-HPMA is a suitable biomarker to
quantify the in vivo level of acrolein after SCI or acrolein-mediated neurodegenerative
diseases (Schettgen et al., 2008; Yan et al., 2010; Park et al., 2013). The acrolein
metabolite 3-HPMA in urine could be detected via liquid chropatography (LC) and mass
spectroscopy (MS), which is an effective technique because of being performed very
quickly.
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Figure 4. Detection of 3-HPMA Level through LC/MS/MS Method
The reaction scheme between acrolein and endogenous antioxidant GSH (A). The result
of LC/MS/MS of acrolein metabolite 3-HPMA level detection. d3-3-HPMA was used as
an internal control (B).
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However, there are difference acrolein levels between 3-HPMA measuring and
immunoblotting acrolein-lysine adduct levels (Park et al., 2013; Zheng et al., 2013).
These discrepancies between two results could be explained through first, limited
diffusion characteristics of acrolein into the blood stream. Second, immunoblotting is
tissue and local specific, but 3-HPMA urine level was detected via systemically; this
increased level cannot be considered to be a specific tissue. So, using these two different
methods could contribute to a more precise detection level of acrolein following SCI.
1.5

Acrolein Scavenging
Because acrolein plays a critical role in secondary cascade events after traumatic

primary SCI, acrolein scavenging would be an effective method to investigate the role of
acrolein in SCI and other neurodegenerative diseases, and to improve motor and sensory
dysfunction after SCI.
Anti-hypertensive medication hydralazine, which is the FDA approved drug, has
been shown to its acrolein scavenging properties (Burcham et al., 2000; Burcham et al.,
2002; Burcham et al., 2004). Hydralazine is a strong nucleophile and it has a hydrazide
functional group. Through hydrazide group, hydralazine can bind to and neutralize
acrolein and acrolein-protein adducts (Burcham et al., 2004; Kaminskas et al., 2004a, b;
Burcham and Pyke, 2006) (structure and reactions between hyalazine and free acrolein
shown in figure 5). Hydralazine reacts with free acrolein and acrolein-protein adduct in
an equimolar manner to neutralize in a cell free system, so equimolar concentration of
hydralazine could eliminate nearly whole acrolein (Zhu et al.; Burcham et al., 2000;
Burcham et al., 2002; Hamann et al., 2008a; Hamann and Shi, 2009).
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Figure 5. Hydralazine Structure and Its Reaction with Free Acrolein
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The reaction products between hydralazine and acrolein were identified as (1E)acrylaldehyde phthalazin-1-ylhydrazone (E-APH) and (1Z)-acrylaldehyde phthalazin-1ylhydrazone (Z-APH)(Zhu et al., 2011). E-APH is the primary reaction product, which
can significantly attenuate the acrolein-induced cellular toxicity and be excreted from
body safely.
Based on previous studies, hydralazine can prevent acrolein-induced PC-12 cells’
death and injuries (Liu-Snyder et al., 2006a; Liu-Snyder et al., 2006b). In addition,
hydralazine also prevents acrolein-mediated allyl alcohol-induced hepatotoxicity in in
vitro hepatocytes (Burcham et al., 2000; Burcham et al., 2004). In addition, hydralazine
can reduce the acrolein-mediated membrane damage, oxidative stress, and loss of
compound action potential (Hamann et al., 2008a; Hamann and Shi, 2009). Furthermore,
the isolated spinal cord ex vivo study showed that hydralazine can alleviate compressioninduced the level of acrolein and acrolein-protein adducts in spinal cord (Hamann et al.,
2008a).
Recent research has demonstrated that hydralazine could reach therapeutic
concentration in 2 hours by systemic injection (Wang et al., 2011). The data has
demonstrated that the level of hydralazine in spinal cord, brain and kidney were higher
than minimum level of hydralazine which could alleviate the acrolein-mediated cellular
death. Because a specific gravity value of spinal cord tissue is 1, the hydralazine level in
the spinal cord can be calculated about 20 μmol/L which is in the range of therapeutic
concentrations, 25 μmol/L (Liu-Snyder et al., 2006a). In addition, compared to
bioavailability of oral application, which is about 40%, bioavailability through systemic
application is about 90% (Hamann et al., 2008a). Taken all together, these results
supported that systemic application of hydralazine may be an effective treatment for
traumatic SCI and acrolein-induced neurodegenerative diseases via scavenging acrolein.
One of limitations of hydralazine is its hypertensive effect. Especially,
vasodilatory effect by hydralazine could be life threatening side effect to SCI patients, as
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they would be get neurogenic shock (Tuncel and Ram, 2003). Short half life of
hydralazine is also another limitation for clinical application of hydralazine. Based on
previous study, half life of hydralazine in vivo is only about 1 hour to 2 hours (Reece,
1981), which is significantly shorter than expected oxidative stress and acrolein
production time window after SCI. However, many of in vitro studies using hydralazine
have demonstrated that acrolein scavenging is an effective ways for intervention to
oxidative stress. Because the hydrazine functional group is in charge of scavenging the
acrolein, developing or investigating an alternative acrolein scavengers without
antihypertensive effect would be needed.
There are other molecules that have a hydrazine functional group like hydralazine.
Their chemical structure can be seen in figure 6. Phenelzine has a hydrazine functional
group which can react with acrolein equimolar manner like hydralazine (Wood et al.,
2006a). In addition, phenelzine is not a vasodilator so it can be used at higher doses than
hydralazine safely and as an alternative to hydralazine. Furthermore, its half life is much
longer than that of hydralazine so it can provide additional neuro-protection effect after
SCI (Shi et al., 2011; Zheng et al., 2013). Even though phenelzine is the FDA approved
anti-depressant, the safety of phenelzine as an acrolein scavenger for clinical application
should be established through further research. Another possible acrolein scavenger is
dihydralazine which has two hydrazine functional groups. Therefore, it could potentially
be twice as efficient as hydralazine’s acrolein scavenging (Kaminskas et al., 2004a).
Dihydralazine has been shown to alleviate the acrolein level in a cell-free system and also
prevent acrolein-induced release of lactate dehydrogenase (LDH) in in vitro hepatocytes
study (Kaminskas et al., 2004b). Taken together, although phenelzine and dihydralazine
can be considered as an acrolein scavenger alternative to hydralazine, researches for their
safety and efficacy should be done first.
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Figure 6. Chemical Structure of Acrolein Scavengers
Hydralazine, dihydralazine, and phenelzine (left to right)
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1.6

Classification of Pain

1.6.1 Nociceptive Pain
Nociceptive pain is an early-warning physiological alarm system which is
mediated by high-threshold unmyelinated C or thinly myelinated Aδ primary sensory
neurons (Woolf, 2007; Woolf and Ma, 2007). This is the normal sensory reaction when
we sense noxious stimulus such as something too hot, cold, or sharp. Only the intense
stimuli (noxious stimuli) that are higher than threshold can activate nociceptive sensory
neuron (Basbaum et al., 2009) and once the noxious stimuli are disappeared, the
nociceptive pain would also be removed. Nociceptive sensory neurons express specific
transducers, mainly transient receptor potential (TRP) channels on C or/and Aδ primary
sensory, which can transmit noxious stimuli into electrical activity (Clapham, 2003; Tai
et al., 2008).
1.6.2 Inflammatory Pain
Inflammatory pain is responsible for responding to tissue damage and the
subsequent immune reaction. This pain is also protective like nociceptive pain in order to
aid healing and repair of the damaged tissues by creating the hypersensitivity to avoid
physical contact and movement (Sandhir et al.; Marchand et al., 2005; Lucas et al., 2006).
Under this condition, normally non-painful factors become painful factors (allodynia) so,
response to normal stimuli and noxious stimuli are exaggerated and lasted (Marchand et
al., 2005; Lucas et al., 2006). In addition, damaged tissues and immune reaction to
infection can result in release of various chemical mediators which create an
inflammatory soup (histamine, serotonin, ATP and bradykinin) (Gilden, 2005; Marchand
et al., 2005; Moalem and Tracey, 2006; Ren and Dubner, 2008). These inflammatory
soups can activate and modify the responsiveness of nociceptor afferents to stimuli
(Glezer et al., 2007). Typically, inflammatory pain is removed by resolving the initial
tissues damage.
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1.6.3 Neuropathic Pain
Neuropathic pain is not adaptive and protective, but maladaptive which results
from both lesion and diseases to the central nervous system (CNS). In addition,
neuropathic pain can result in both neurological disorders and pain (Scholz and Woolf,
2007). Under this condition, nociceptive pathway could be changed by peripheral
sensitization and central sensitization so that normally non-painful factors produce the
pain (allodynia) and response to noxious stimuli could be enhanced (hyperalgesia)
(Zimmermann, 2001; Campbell and Meyer, 2006; Costigan et al., 2009a). Peripheral
sensitization indicates that a reduction in threshold and an increase in sensitivity at the
nociceptor in peripheral terminal ending. It can result in the pain hypersensitivity at the
tissue damage and inflammation (Zhuo, 2007; Costigan et al., 2009a). Central
sensitization is an increase in the excitability of sensory neuron in the CNS, which results
from damage or/and diseases. Under the central sensitization, normal sensory information
begins to generate abnormal responses so, low-threshold primary afferent sensory
neurons which are activated by innoxious stimuli can activate neurons in the spinal cord
and/or the brainstem that normally respond to only noxious stimuli (Zimmermann, 2001;
Zhuo, 2007; Costigan et al., 2009a). In addition, after damage to the CNS, the immune
cells are activated in the CNS, which increase the release of cytokines and also lead to
central sensitization (Costigan et al., 2009b; White et al., 2009).
1.7

Chronic Neuropathic Pain after Traumatic Spinal Cord Injury
Chronic neuropathic pain is commonly found in SCI patients. Based on the

previous studies, traumatic SCI could lead to a chronic neuropathic pain within months
(Richards et al., 1980) and more than 80% of SCI patients suffer from significant pain
which is felt as burning and stabbing (Siddall et al., 2003). As a matter of fact, beyond
paralysis, chronic neuropathic pain further drastically impairs the quality of life for SCI
victims. Despite years of research, this type of clinical pain remains refractory to
treatment. As a result, chronic neuropathic pain could be prolonged for several decades
after SCI and leads to depression and suicide (Segatore, 1994; Cairns et al., 1996). There
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are several possible mechanisms that can explain the generation of chronic neuropathic
pain after SCI (Scholz and Woolf, 2002; Basbaum et al., 2009; Costigan et al., 2009a;
Milligan and Watkins, 2009).
First, after neuronal damage, the central terminal of non-nociceptive primary
afferents Aβ fibers could make new synaptical connections with nociceptive neurons in
laminae I and II. This re-connection and sprouting in the nociceptive pathway can result
in persistent pain hypersensitivity
Second, changing in glutamatergic neuron and N-methyl-D-aspartate (NMDA)
receptor mediated sensitization. Under the normal condition, pain is transmitted by
release of glutamate from the central ending of nociceptor neurons, which is generating
excitatory postsynaptic currents (EPSCs) in secondary order neuron in the spinal cord
dorsal horn interneurons. However, under the neuropathic pain condition, increased
release of glutamatergic neurotransmitter from central ending of nociceptors would
sufficiently depolarize and activate postsynaptic NMDA receptors. As a result, an
increased in calcium influx can activate calcium-dependent signaling transductions such
as MAPK, PKC and PI3K, which could keep activating the dorsal horn pain transmission
resulting in exacerbating sensitivity to noxious stimuli.
Third, after neuronal damage, the loss of function of GABAergic and/or glycinergic
inhibitory interneurons could result in increased sensitivity. Under normal physiological
condition, inhibitory interneurons continuously release inhibitory neurotransmitters such
as Gamma-aminobutyric acid (GABA) and/or glycine to alleviate the excitability of
lamina I interneurons and modulate pain transmission. However, under the setting of
neuropathic pain physiology condition, there are loss of inhibitory effects (disinhibition),
which contribute to the generation of allodynia and hyperalgesia. Disinhibition can make
non-nociceptive myelinated Aβ primary afferent to involve in pain transmission circuitry,
so normally innoxious stimuli are perceived as painful stimuli.
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Lastly, glial cells such as microglia and astrocytes also can lead to chronic
neuropathic pain after SCI. Under normal conditions, microglias act as resident
microphages in the CNS. After injury within hours, microglias accumulate in the
superficial dorsal horn and they release various cytokines and chemokines which can
induce the central sensitization and persistent pain. However, in contrast to microglia, an
activation of astrocyte is normally delayed and prolonged up to several months, which
indicate that astrocytes may play an important role for the maintenance of persistent pain
and induction of central sensitization after SCI.
1.8

The Role of Reactive Oxygen Species in Neuropathic Pain
Recent studies have shown that ROS are also implicated in neuroapthic pain

(Yowtak et al.; Kim et al., 2004; Park et al., 2006; Gao et al., 2007). Kim et al showed
that the nerve ligation induced-neuropathic pain allodynia significantly reversed after
treatment with various ROS scavengers (Kim et al., 2004; Kim et al., 2006). This data has
demonstrated that ROS could play a critical role in the maintenance of neuropathic pain.
As we already discussed about the role of NMDA receptors in central sensitization after
SCI, an increased in the phosphorylation of NMDA receptor in the spinal dorsal horn is a
one of the key factors for inducing the neuropathic pain and central sensitization. In
addition, previous study has showed that oxidative stress in the spinal cord also
contributed to maintaining a high level of phosphorylation of NMDA receptors in dorsal
horn which results in central sensitization. Furthermore, elevated levels of ROS in the
spinal cord can activate various protein kinases such as PKA and PKC, which again
elevate the level of phosphorylation of NMDA receptor. In addition, Gao et al have
demonstrated that the level of activated NMDA receptors in the dorsal horn and
neuropathic pain behaviors were significantly attenuated by systemic application of ROS
scavenger in neuropathic pain animal model (Gao et al., 2007). These studies indicate
that ROS are implicated in phosphorylation of NMDA receptor which results in
neuropathic pain behavior after SCI, and ROS scavengers can be used as analgesic by
blocking ROS-related signaling pathways after SCI.
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Again, another important mechanism that induces the chronic neuropathic pain was
loss of inhibitory function after neuronal damage (in section 1.7). Several recent studies
have demonstrated a sensitivity of GABA neurons to oxidative stress. Virgili et al
showed that an antioxidant resveratrol, which was found in red wine could promote
neuroprotective effect in vivo because it could selectively alleviate the reduction in
GABA synthesizing enzyme levels in rat (Virgili and Contestabile, 2000). In addition,
Chen et al have demonstrated that superoxide, which is a type of ROS, could lead to
presynaptic inhibition of GABA release to postsynaptic neuron (Chen and Pan, 2007).
This study indicated the vulnerability of GABA neuron to oxidative stress. One recent
study showed that increase levels of spinal ROS can promote neuropathic pain behaviors
such as mechanical hyperalgesia in normal mice, which was very similar to the pain
behaviors in peripheral nerve injury-induced neuropathic pain animal model. In addition,
they showed that ROS were critically involved in reducing presynaptic inhibitory GABA
neurotransmitter release in neuropathic pain animal model. However, when they treated
them with ROS scavengers, ROS-mediated effects were reversed. These data indicate
that ROS promote the pathogenesis of neuropathic pain following SCI by interfering with
the inhibitory function of the spinal GABAergic system, and ROS scavengers could
effectively attenuate neuropathic pain behaviors, which are achieved through the restore
of GABA-mediated inhibitory system. Furthermore, many of byproducts of oxidative
stress could activate TRP channels on the nociceptive sensory neuron, which transmit the
pain signaling to the CNS (Bautista et al., 2006). We will discuss about this in sections
1.9 and 1.10 more specifically.
1.9

Acrolein-mediated Sensory Dysfunction after SCI
Although many of studies have demonstrated the role of ROS in neuropathic pain

following SCI (Kim et al., 2004; Chen and Pan, 2007; Gao et al., 2007; Yowtak et al.,
2011), There are a few studies about acrolein and acrolein-protein adduct-mediated
neuropathic pain after SCI. As a self-regenerative molecule, acrolein can generate
additional acrolein and promote oxidative stress even with micro-molar levels of acrolein,
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which indicate that acrolein may promote pathogenesis of neuropathic pain through
oxidative stress after SCI (Luo and Shi, 2004).
Many studies have shown that acrolein, is a neuropathic pain inducer after SCI
through the transient receptor potential ankyrin 1 (TRPA1) (Bautista et al., 2006; Nilius
et al., 2007; Andersson et al., 2008; Bessac et al., 2008). Specifically, TRPA1 channel act
as sensor for byproducts of oxidative stress-derived molecules and of metabolisms. As a
TRPA1 agonist, acrolein can bind to TRPA1 directly and activate TRPA1 channel
(Bautista et al., 2006). Based on previous studies, gene expression level of TRPA1 is
increased in the spinal dorsal horn and dorsal root ganglia (DRG) after SCI
(Venkatachalam and Montell, 2007; Due et al., 2014).
Due et al. have demonstrated that mechanical and cold allodynia could be observed
in 2 weeks after SCI and lasted several weeks (Due et al., 2014). Also, data have shown
that there was increased in expression level of acrolein at least 2 weeks after SCI, which
was in coincidence with neuropathic pain mechanical and cold allodynia (Due et al., 2014;
Park et al., 2014). Furthermore, Due and colleagues have shown that expression of
TRPA1 messenger RNA (mRNA) level was increased seven days after SCI using lumbar
level of DRG cells, which indicated that acrolein could contribute to generation of
neuropathic pain even its level returned to normal physiological concentration after SCI.
Furthermore, acrolein also acts as pro-inflammatory factor so that they can stimulate the
release of chemokines after neuronal damage (Boddeke, 2001; Kirkham et al., 2003;
Hulsebosch et al., 2009). Previous study has also shown that chemokine which was
produced by pro-inflammatory factors such as acrolein could activate TRPA1 channel
(Jung et al., 2008). In this sense, acrolein, both as a TRPA1 agonist and as a proinflammatory factor, it can activate TRPA1 channel directly and indirectly through
chemokine-medicated signaling pathways.
An incidence of spontaneous activity and an increase in overall excitability state of
DRG sensory neuron also are responsible for emergence and maintenance of neuropathic
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pain after SCI other than acrolein level increase (Due et al., 2014). In this study, the data
indicated that there was a decrease in the current threshold, which is minimum current to
generate single action potential, in small and medium diameter of sensory neuron after
SCI. In addition, there was an increase in number of DRG cells that responded to acrolein
following SCI. Furthermore, acrolein could increase the excitability of sensory neuron at
single DRG cell level, and acrolein-mediated sensory excitability was greater in the SCI
group compared to the sham injury control group. The effect of acrolein in increase of
sensory neuron’s excitability was further supported by Park and colleagues’ data. They
have shown that exogenous injected acrolein into the spinal cord could promote not only
the mechanical allodynia, but motor function and neuronal tissue deficits (Park et al.,
2014). Taken results of electrophysiology and in vivo acrolein injection together, acrolein
can be considered as an endogenous pro-nociceptive factor after SCI.
Based on current understanding and results from research, acrolein could be an
effective therapeutic target as a pro-nociceptive and pro-inflammatory factor. The
involvement of acrolein in chronic neuropathic pain after SCI was further demonstrated
using acrolein scavenger hydralazine studies (Due et al., 2014; Park et al., 2014). The
data showed that systemic application of hydralazine significantly attenuated mechanical
and cold allodynia after SCI. The benefits of hydralazine as an analgesic lasted for
several weeks and even worked two weeks delayed hydralazine application. This data
indicated that acrolein scavenger hydralazine could prevent acrolein binding to TRPA1
channel and alleviate the acrolein-mediated inflammatory events after SCI.
These recent studies have demonstrated that acrolein could be a key therapeutic
target in the generation of neuropathic pain after SCI, and acrolein scavenger such as
hydralazine, could be an effective therapeutic strategy to attenuate neuropathic pain for
promoting the SCI victims’ quality of life.

23
1.10 General Characteristic of TRPA1 Channel and Its Activation by Acrolein
TRPA1 channel is a non-selective cation calcium ion channels and consists of six
trnasmembrane segments (Doerner et al., 2007; Andre et al., 2009; Patapoutian et al.,
2009). The N-terminal and C-terminal of TRPA1 channel are located in the intracellular
side of membrane. Especially, the long N-terminal contains up to 18 ankyrin repeated
domains which are involved in the activation of TRPA1 channel. On this ankyrin
repeated domain, there is EF-hand domain where calcium ions can bind to and activate
TRPA1 channel. So, calcium ions play a critical role in TRPA1 functioning (Clapham et
al., 2001; Bandell et al., 2007). In addition, N-terminal cystein residues are responsible
for electrophile-mediated TRPA1 channel activation.
The gene expression level of TRPA1 was increased in the spinal dorsal horn and
DRG after SCI (Due et al., 2014). TRPA1 channels have a wide pore which is stimulus
dependent so that it can regulate the calcium ions permeability (Bandell et al., 2007). In
this sense, SCI-induced neuropathic pain can increase not only the expression level of
TRPA1 channels, but the pore size, which lead to influx of much larger calcium ions
compared to normal physiological condition. Furthermore, TRPA1 channels are
expressed in C and Aδ primary afferent fiber and many of TRPA1-expression neurons
are peptidergic neurons which contribute to release of neurotransmitters to postsynaptic
neurons (Bautista et al., 2006). So, TRPA1 channel on the central ending of primary
afferent neuron in the spinal dorsal horn might play an important role in the maintenance
and transmission of pain signaling.
Based on previous studies, TRPA1 channel acts as a sensor for endogenous
byproducts of oxidative stress-mediated substances (Andersson et al., 2008). These
byproducts such as acrolein, 4-HNE and H2O2 can directly activate TRPA1 channel
because of the electrophilic properties of compounds. These electrophilic compounds
react with nucleophilic thiol group of cystein and ε-amino group of lysine residues in the
N-terminal of TRPA1 channel via covalent modification. In addition, the reaction
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between acrolein and thiol group of cystein is reversible so acrolein can break from
cystein-acrolein adduct and bind to other proteins and/or DNA. Under normal
physiological pH and temperature, covalent modification on the channel lasts for hours
which contribute to conformational change of TRPA1 channel. Therefore, membrane
permeability is the one of the critical fundamental requirements for TRPA1 channel’s
agonist (Bautista et al.; Bautista et al., 2006; Andersson et al., 2008; Bessac et al., 2008).
Another possible activation of TRPA1 channel by byproducts of oxidative stress is the
formation of disulfide bond via oxidation by hydrogen peroxide and again, this
modification of N-terminal cystein in TRPA1 results in wide the pore size of the channel
(Bautista et al., 2006; Nilius et al., 2007; Patapoutian et al., 2009).
Other non-electrophilic TRPA1 agonists such as menthol, camphor and icilin do
not bind to cystein or lysine residue covalently because of their chemical structure
(Bandell et al., 2004; Bandell et al., 2007). These agonists can stimulate TRPA1 channel
through a temporal and reversible Fischer lock and key principle. In general, anesthetic
agents such as lidocaine can promote the activation and sensitization of TRPA1 channel
(Matta et al., 2008; Piao et al., 2009). Normally these anesthetic agents depress the CNS,
but also activate peripheral nociceptive sensory neurons by activating TRPA1 channel.
Furthermore, these effects could integrate with tissue damage during the surgical
operation, which could result in an increase in post-operative pain and inflammation.
TRPA1 channel also can be activated indirectly through G-protein coupled receptor
(GPCR)-mediated pathway (Bautista et al., 2006). For example, TRPA1 can be activated
by pro-inflammatory factor bradykinin (BK)-induced signaling pathway. When BK binds
to its receptor (bradykinin 2 receptor), intracellular calcium level is increased through a
phospholipase C (PLC)-mediated down-stream signaling. These calcium ions could bind
to EF-hand domain of N-terminal of TRPA1 and lead to activation of TRPA1 channel. In
addition, TRPA1 can be also activated via transient receptor potential vanilloid1
(TRPV1). TRPA1 channel is most likely expressed with TRPV1 channel. TRPV1 can be
sensitized by binding of its agonists such as capsaicin or/and by secondary messengers
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such as PKC. In addition, heat thermal stimulus can activate the TRPV1 channel. TRPV1
channel activation lead to an increase in influx of calcium ions into the cytoplasm, and
these calcium ions could bind to TRPA1 and results in activation of TRPA1 channel.
Therefore, TRPA1 gates in response to both calcium ions release from intracellular
calcium ion stores and influx calcium ions after gating TRPV1 channel(Bautista et al.;
Hinman et al., 2006; Andersson et al., 2008; Bessac and Jordt, 2008).
1.11 Summary and Conclusion
There is strong evidence that acrolein acts as key factor in secondary cascade
events after primary traumatic SCI. With its reactive, volatile, long half-life and ability to
generate protein adducts nature, acrolein has been associated with many different types of
neurological diseases.
In addition, as a strong pro-nociceptive agonist, acrolein can promote sensory
neurons’ excitability, and reduction current threshold of sensory neuron after SCI.
Although, more studies are needed to understand the mechanisms about elevation of
sensitivity on nociceptive sensory neuron via TRPA1 channel or/and acrolein alone,
many of studied have demonstrated that acrolein could be a valuable therapeutic target to
improve the SCI-induced neuropathic pain and neurological deficits.
Many of recent studies have demonstrated that acrolein scavenger hydralazine can
attenuate acrolein-mediated cellular death and toxicity. In addition, hydralazine can
decrease the acrolein-protein adduct level and offer the neuroprotective effects in in vivo
SCI animal model. Because half-life of hydralazine is only a few hours (2hours), it might
be possible that frequent application of hydralazine would provide additional
neuroprotective effects. Taken all together, acrolein-scavenging strategies might be a
novel and potential way to improve quality of patients’ life, who are suffering from SCI
and acrolein-mediated neurological diseases.
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CHAPTER 2. NEUROPROTECTIVE ROLE OF ACROLEIN SCAVENGER IN
SPINAL CORD INJURY RAT MODEL

2.1

Introduction
Secondary cascade biochemical events after primary traumatic SCI can result in

spreading the additional damages throughout the spinal cord and amplify the effects of
traumatic SCI.
Post-traumatic oxidative stress, as a key factor of secondary cascade, plays a
critical role in the pathogenesis and in mediating functional loss of SCI (Braughler and
Hall, 1989b). However, treatment with free radical scavengers have been failed to
produce effective results on clinical trials. We have been demonstrated that acrolein,
byproduct of LPO and α,β-unsaturated aldehyde, plays an important role in neuronal cell
death and secondary cascade events after traumatic injury (Shi and Luo, 2006; Hamann et
al., 2008b; Hamann and Shi, 2009; Shi et al., 2011). Basically, acrolein is very reactive
and volatile molecule, which concentration is increased in the spinal cord after SCI. In
addition, with its significantly long half-life, it can stay within biological system
compared to other types of ROS (Esterbauer et al., 1991a; Ghilarducci and Tjeerdema,
1995; Picklo and Montine, 2001; Shi et al., 2002a; Luo and Shi, 2004; Liu-Snyder et al.,
2006b; Shi and Luo, 2006). Furthermore, acrolein can bind to proteins, DNA, and lipid
directly and induce the formation of acrolein-protein adducts (Kehrer and Biswal, 2000b;
Stevens and Maier, 2008). In addition, with acrolein’s neurotoxicity nature, many studies
have been also shown that acrolein has been implicated in many of neurodegenerative
diseases such as degrading myelin (Luo et al., 2005a; Liu-Snyder et al., 2006b).
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Therefore, acrolein can induce a vicious cycle of oxidative stress and amplifies its
effects, and also it is responsible for spreading of additional damage throughout the spinal
cord tissue after traumatic SCI.
Because of important pathological role of acrolein, the detection and measurement
techniques of acrolein are very important to investigate the acrolein-mediated
neurodegenerative diseases. Recent study has shown that stable acrolein specific
metabolite 3-HPMA was generated when acrolein reacted with endogenous antioxidant
GSH, which could be measured in urine (Carmella et al., 2007; Schettgen et al., 2008).
Because of its non-invasive method, measuring 3-HPMA has been using to estimate the
level of acrolein such as acrolein intake via smoke and food (Schettgen et al., 2008).
Based on current understanding of acrolein, we hypothesize that attenuation of
acrolein might reduce neurological damage and improve the functional recovery after
SCI. To investigate this hypothesis, and to demonstrate the role of acrolein in SCI, we
have investigated that the acrolein scavenger, hydralazine, could mitigate acroleinmediated cell death (Liu-Snyder et al., 2006b), as well as in isolated spinal cord (Hamann
et al., 2008a).

In addition, hydralazine could prevent acrolein-mediated toxicity in

hepatocytes via in vitro test and delayed onset of multiple sclerosis (MS)-induced motor
neuron dysfunction in mice (Leung et al., 2011b). Although there are many of in vitro
studies that have investigated the effect of acrolein-scavenger hydralazine via in vitro test,
anyone hasn’t evaluated the effect of acrolein scavenger therapy using in vivo SCI animal
model. Without this information, the effect and therapeutic value of acrolein for treatment
for SCI patients remain uncertain.
In this sense, the primary goal of this chapter is to ascertain the pathological role of
acrolein in the CNS and the effect of acrolein scavenger hydralazine in live SCI animal
model. Through this study, we also investigate whether the FDA-approved hypertensive
medication hydralazine can attenuate acrolein-mediated tissue damage and promote
functional recovery.
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2.2

Material and Methods
Animal
Body weight between 210-230 grams male Sprague-Dawley rats were used for this

study. Rats were housed and handled in compliance with the Purdue University Animal
Care and Use Committee guidelines. For the acclimation, the animals were kept at least
one week before surgery.
Contused- spinal cord injury rat model
Animals were anesthetized with a ketamine (80 mg/kg) and xylazine (10 mg/kg)
mixture by an intraperitoneal (IP) injection. A dorsal surface of spinal cord at the T-10
level was exposed by removing spinous process and vertebrae lamina. We made two
different severities contusion models by using New York University (NYU) impactor.
Basically, NYU impactor has a 10-gram of weight rod with 1.5 mm. By dropping this
weight rod from different height, we can generate different severity of contused-SCI
model. In this study, we dropped the weight rod form 25mm onto the intact T-10 level of
spinal cord to generate moderate contused-SCI model. For severe contused-SCI model,
we dropped it onto the spinal cord from 37.5mm. The sham control was operated using
only a laminectomy at the T-10 level. For the post-surgical care, the animals were placed
on a heating pad and performed manual bladder expression daily two times until the
reflexive control bladder function was observed, and to prevent dehydration, 3.0 cc of
saline was injected through subcutaneously.
Hydralazine treatment
The hydralazine hydrochloride (Sigma, St. Louis, MO, USA) was dissolved in
sterilized phosphate buffered saline (PBS). 5mg/kg of hydralazine solution was injected
via I.P. injection daily for two weeks, right after SCI within 5 minutes. For
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immunoblotting study, hydralazine solution was administrated by I.P. injection right after
surgery and 24 hours after SCI. Then, animals were euthanized two hours injection to
collect spinal cord injury sites. The dosage of hydralazine solution 5mg/kg was decided
based on previous study (Zheng et al., 2013). They have demonstrated that 5mg/kg of
hydralazine showed not only the effectiveness of acrolein reduction, but the minimal
influence of blood pressure to the animals.
Quantification of hydralazine in the central nervous system
Paper spray mass spectrometry was used to quantify the concentration of
hydralazine in the spinal cord, and brain. To quantify the concentration of hydralazine in
the tissues, first, we collected tissues from the untreated animals, which were spiked
artificially with different concentration of hydralazine from 15.63 ng/ml to 2000 ng/ml.
For the internal control, the fixed concentration of nicotine was used. Based on these data,
we constructed a calibration curve. In the experiment group, saline was injected as a
control and 5mg/kg of hydralazine was injected then, animals were sacrificed two hours
after injection. Collected samples were punched and transferred onto the paper for paper
spray mass spectrometry analysis and measurement of hydralazine level. The final
concentration of hydralazine was calculated by using calibration curve fits.
Urine collection
For the urine collection from the animals, we used the standard metabolic cages.
Drinking water and urine collection were separated to avoid urine dilution by water
source. During the urine collection, food was also provided. To collected enough urine
for the study, 0.5 cc of saline was injected via subcutaneously at each collection time.
Sometimes to collect sufficient urine, we performed manually press the rat bladder.
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Creatinine measurement
We measured the creatinine level with a creatinine (urinary) assay kit (Cayman
Chemical Company, Item No. 500701). Original urine sample were diluted for 12 and 24
times before the creatinine assay. According to the assay manual, all required agents were
prepared. Then, all diluted urine samples and creatinine standards were incubated on the
shaker with the alkaline picrate solution for 15 mins. Using standard spectrophotometry,
the samples were read at 492 nm then, 5 ul of acid solution were added to all samples
after initial reading. The plate also was placed on the shaker for 15 mins. The differences
wave absorbance between the initial reading and final reading were used for analysis.
3-hydroxypropyl mercapturic acid (3-HPMA) Analysis in Urine
3-HPMA was analyzed in urine according to Eckert et al (Eckert et al., 2010). For
using LC/MS/MS solid phase extraction with isolute ENV+ cartridge (Biotage, Charlotte,
NC) was used to prepare each sample. Each cartridge was washed with 1ml of methanol,
1 ml of water, and 1 ml of 0.1% formic acid in water. A volume of 500 µl deuterated 3HPMA (d3-3-HPMA) were spiled with 200ng, which was then mixed with 500 µl of
50mM ammonium formate and 10 µL of undiluted formic acid. This mixture was loaded
into the ENV+ cartridges. After the samples loading, using 1 ml of 0.1% formic acid, and
1 ml of 10% methanol/90% 0.1% formic acid in water, washed each cartridge twice. Next,
under the nitrogen gas, the cartridges were dried for 30mins, then, using three volumes of
600 µl methanol with 2% formic acid, all cartridges were eluted. The eluates were dried
in the evaporate device. Right before loading the samples into the LC/MS/MS, each
sample was reconstituted in 100 µl of 0.1% formic acid. The LC/MS/MS using and data
analysis were performed based on Zheng et al (Zheng et al., 2013).
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Locomotor behavioral test
The functional motor neuron recovery was investigated by using the Basso, Beattie
and Bresnahan (BBB) Locomotor Rating Scale (Basso et al., 1996). The BBB locomotor
scores are based on the ability of SCI rat’s hind limb movement. For example, BBB score
0 means that there is no observable movement of rat’s hind limb, and 21, which is
maximum score, means that movement of normal rat. For the test, the rats were placed in
an open field for 5 mins for the acclimation, then observe the movement of left and right
side of hind limb separately. BBB score were assessed at day one and weekly for four
weeks after SCI.
Neuropathic pain assessment
50% up-down method was used for mechanical allodynia test (Chaplan et al., 1994).
Briefly, SCI animals were placed in a plastic acrylic box on the top of a metal mesh. For
the acclimation, left them alone at least 10 mins then test was performed by using von
Frey filaments. As mechanical stimuli, we used calibrated von Frey filaments which
range from 0.4, 0.6, 1.0, 2.0, 4.0, 6.0, 8.0 and 15.0 grams (stoelting, Wood Dale, IL,
USA). Initially, 4 grams of von Frey filament was applied perpendicularly with a
sufficient bending force to the plantar surface of the hind-limb for 3-5 sec then removed.
A brisk movement and/or licking and/or biting were considered as a positive reaction,
then a lower von Frey filament was applied to the same spot. If there was no positive
response, the next greater filament was presented. Different stimulus of filaments were
applied at least 1 min interval.
Isolation of spinal cord
Initially, animals were anesthetized deeply with a mixture of ketamone (80mg/kg)
and xylazine (10mg/kg) via I.P. injection. Then, they were perfused with oxygenated cold
Kreb’s solution (124mM NaCl, 2mM KCl, 1.24 mM KH2PO4, 26 mM NaHCO3, and 10
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mM ascorbic acid, 1.3 mM MgSO4, 1.2 mM CaCl2, and 10 mM glucose). To isolate
spinal cord, first, the whole vertebral column of rat was removed and we performed a
dorsal laminectomy along the vertebral column. Collected spinal cord was cut into 1 cm
long for immnoblotting for acrolein level detection and for histological analysis.
Artificial acrolein standard preparation
For the immunoblotting, the artificial acroelin standard was prepared. Initially, rat
albumin (0.5 ml of 2mg/ml, CalBioChem) solution and acrolein (0.5ml of 100 mM,
Sigma) solution were mixed together, which was incubated for 4 hours at 37 degree C.
Using 0.1% BSA, we performed serial dilution up to 10000 fold with the acrolein
concentration ranging from 5uM (or 100ng/ml) to 25nM (or 0.5ng/ml). The standard
smaples were loaded and measured, then we measured the band intensities by using
Image J (NIH). Based on these bands density, we constructed the calibration acrolein
standard curve. So, acrolein level in the interest samples can be measured from this fitted
standard curve.
Immunoblotting
Spinal cord segments which include damage site were incubated with a 1% Triton
solution with the corresponding amount of Protease Inhibitor Cocktails (Sigma Aldrich),
then homogenized with sonicator for 10 sec. The homogenized tissue suspension was
incubated in the ice for 1 hour then, centrifuged at 4 °C at 13500g for 30 mins. Using
BCA protein assay kit, we measured the total protein concentration from each sample for
the equal sample loading. 200μg of samples were transfer to the nitrocellulose membrane
by using a Bio-Dot SF Microfiltration Apparatus (Bio-Rad, Hercules, CA, USA). Next
this transferred membrane was blocked in 0.2% casein and 0.1% Tween 20 in PBS
blocking buffer for 1 hour and incubated with monoclonal mouse anti-acrolein antibody
(ABCAM) for at least 18 hours at 4 °C. An anti-acrolein antibody was diluted at a ratio
of 1:1000 in blocking buffer with 2% goat serum and 0.025% sodium azide. The
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membrane was washed 4 times in blocking buffer for 4 mins then, the membrane was
transferred to 1:10000 alkaline phosphatase conjugated goat anti-mouse IgG solution for
another hour (VECTASTAIN ABC-AmP Kit). For the final washes, we used blocking
buffer and 0.1% Tween 20 in Tris-buffered saline then, the membrane was exposed to
substrate of the ABC-AMP kit and visualized by chemiluminescence. The band density
was assessed by Image J (NIH) and using an arbitrary unit for the expression.
Histology of rat spinal cord injury
For the tissue collection, initially we perfused animals with oxygenated cold Kreb’s
solution then followed by 10% formalin. The removed spinal cord was into 10% formalin
for the post fixation for 24 hours then, embedded in paraffin. Tissues were cut with 10
µm thickness through horizontal section and stained with luxol fast blue and cresyl violet.
The cyste area was quantified by measuring the percent area of the cyst relative to the rest
tissue area on the section, then we took an average two adjacent sections at the spinal
cord mid-line. The area was compared between hydralazine treatment and non-treatment
group with a Student’s T-test.
Acrolein microinjection into spinal cord and histological analysis
After deep anesthesia, we performed laminectomy at T-10 level to expose intact
spinal cord. The micro-pipettes were pulled and beveled for the insertion into the spinal
cord. Micro-pipette was loaded with saline as a control and acrolein in saline as an
experimental group. The solution was injected using a three-way valve and a syringe
under the negative pressure. For the injection, we used the PMI-100 oressure microinjector (Dagan Corp., Minneapolis, MN). 1.6 µl of saline was injected into rat’s left side
of spinal cord as a control and 1.6 µmol of acrolein in saline was injected into rat’s right
side of spinal cord. Specifically, each solution was injected 0.6 mm lateral to the spinal
cord mid-line and 1.2 mm ventral to the spinal cord surface at T-10 level. For the post-
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surgical care, rat was placed on the heating pad and anti-biotic ointment was applied to
the incision site.
For the histological analysis, we performed hematoxylin and eosin staining on the
spinal cord 2 weeks after surgery. Paraffin embedded spinal cord samples were cut into
longitudinally with 15 µm thickness by using AO829 microtome (American Optical,
Buffalo, NY). After staining with hematoxylin and eosin, images were acquired by
Olympus microscope at 4X and followed by Image J for the analysis.
Statistical analysis
For the data comparison between two groups, we performed Student’s t-test
method and for the more than two variables, we used ANOVA and Tukey test. If the p
value is smaller than 0.05, we considered the data is statistically different. All the
averages were expressed in mean േ SEM.
2.3

Results
The increase of acrolein level after SCI
We have measured the acrolein level after SCI by using immunoblotting. The data

have shown that acrolein level was significantly increased in moderate and severe SCI
compared to the acrolein level in sham control group at both 1 day and 14 days after SCI
(Figure 7). Specifically, the levels of acrolein in sham, moderate, and severe SCI were
9.1±5.3, 31.1± 4.0, and 42.7±3.1 respectively. There were significantly difference in
acrolein level between sham and moderate SCI also between sham and sever SCI group
at 1 day after SCI. Similar to this, acrolein levels in 14 days after SCI were 8.5±3.6,
15.3±4.0, and 34.7±3.6 respectively. There were statistically differences in acrolein level
between sham and severe SCI group.
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Figure 7. Elevation of Acrolein Level in Spinal Cord Based on the SCI Severity.
Acrolein-lysine adduct level based on the SCI severity was detected by using
immunoblotting at different time points (1 day and 14 days after SCI). The bar graph
showed that acrolein levels were significantly increased in moderate and severe SCI
compared to sham control group at both 1 day and 14 days after SCI. In addition,
acrolein level was correlated with SCI severity which indicated that sever SCI
showed the highest level of acrolein. This data also indicated that acrolein level was
persisted at least 14 days following SCI. For the comparison, acrolein arbitrary unit in
moderate and severe were 31.09± 4.0 and 42.69±3.13, which were significantly
higher than that of shame (9.13±5.29, p <0.005) at day 1. Also, acrolein level in
severe SCI at day 14 was 34.73±3.64, which was also significantly higher than that of
sham (8.53±3.57, p<0.005). There was no difference between moderate and sham at
14 days after SCI. For the data analysis, one way ANOVA and post hoc tests were
used. N=6 in all groups.
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Elevation of urine 3-HPMA levels from SCI
To determine the endogenously generated acrolein level after SCI, we
measured the 3-HPMA level using rat urine samples from different SCI severity
groups. Similar to acrolein level in different SCI severity group, 3-HPMA levels also
were correlated with SCI severity (Figure 8). Specifically, we collected rat urine 24
hours after SCI and 3-HPMA levels were 1.99±0.21, 3.51±0.24, and 5.51±1.13 μg/mg
in sham, moderate and severe SCI group. These data showed that 3-HPMA level of
moderate SCI was higher than that of sham (p<0.05) and 3-HPMA level of severe
group was also higher than that of moderate SCI (p<0.05). Taken together, elevation
of 3-HMPA level also correlated with SCI severity.
The level of hydralazine in CNS following IP injection
Before test the benefit of acrolein scavenger hydralazine, we investigated
whether it could reach therapeutic level in the CNS after I.P injection. According to
the previous study, half-life of hydralazine was about 2 hours, so we euthanized the
animals 2 hours after hydralazine systemic application (5mg/kg) and then, the brain
and spinal cord was removed. Hydralazine level was measured by using paper spray
mass spectrometer. The results data has shown in figure 9. First of all, there were
significant levels of hydralazine in the CNS within two hours after systemic
application. Specifically, the detected level of hydralazine in the brain and spinal cord
were 2.92 ± 0.88 and 4.42 ± 1.11 µg/g (29.47 ± 4.65 and 19.87 ± 4.42 µM), while,
there was no detected hydralazine concentration in control group. Based on previous
in vitro test, minimal level of hydralazine to attenuate acrolein-mediated cellular
death was no higher than 20 µM. So, this data indicated that hydralazine could reach
the CNS using systemic application and its concentration was enough to provide the
neuroprotection effect.
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Figure 8. Correlation of 3-HPMA Level with SCI Severity
The urine samples from sham control, moderate SCI, and severe SCI were collected
24 hours after SCI for the 3-HPMA study. Similar to acrolein level, 3-HPMA level
also correlated with SCI severity. The 3-HPMA levels were 1.99±0.21, 3.51±0.24,
and 5.51±1.13 μg/mg respectively. Specifically, 3-HPMA level in severe SCI showed
the highest level compared to any other groups. N=4-6 for each group. For the
statistical analysis, one way ANOVA and Turkey test were used ( כP < 0.05)
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Figure 9. Detection Hydralazine Level in the CNS after Systemic Application.
A) 5mg/kg of hydralazine solution was injected through systemically and same
amount of saline was used for the control group. Two hours after injection, the brain
and spinal cord tissues were removed to determine level of hydralazine. B)
hydralazine level was determined using paper spray mass spectrometer. The data
showed that level of hydralazine in the CNS were 29.47 ± 4.65 and 19.87 ± 4.42 µM
respectively. No hydralazine level was detected in saline control group. This data
demonstrate that systemic application of hydralazine could reach the CNS within two
hours and could provide neuroprotective benefits. N=4 in all groups.
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Acrolein scavenger hydralazine can effectively decrease acrolein level in
SCI animal model
We have confirmed that hydralazine could reach the CNS with the therapeutic
level. Next, to test if the acrolein scavenger hydralazine could reduce the acrolein
level after SCI, we injected 5mg/kg of hydralazine right after SCI surgery within 5
mins and gave the second injection two hours before the animals were euthanized. As
shown in figure 10, acrolein scavenger hydralazine could significantly reduce the
acrolein-lysine adduct level after SCI. The data indicated that in both moderate SCI
and severe SCI, the levels of acrolein were reduced by more than 50% after
hydralazine application. This data supported that acrolein scavenger hydralazine
could reduce the acrolein level after SCI effectively.
Acrolein scavenger hydralazine can decrease the urine 3-HPMA level
after SCI
Again, urine 3-HPMA level was measured to confirm the effect of hydralazine
as an acrolein scavenger. For this study, 5mg/kg of hydralazine was injected for seven
days daily and urine also collected every 24 hours for seven days. Initially, 3-HPMA
level was significantly increased in SCI group in the first three days after operation
(Figure 11). Specifically, 3-HPMA levels were 3.51±0.24, 2.96 ±0.20, and 2.49±0.12
μg/mg, respectively. However, 4 days post injury, the level of 3-HPMA were as low
as that of control. Hydralazine treatment group showed that the level of 3-HPMA at
one day after SCI was significantly lower than that of SCI only group. However, there
was no difference between hydralazine treatment group and SCI only group in the
remaining period.
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Figure 10. Hydralazine can Reduce the Acrolein-lysnie Adduct Level after SCI
Using immunoblotting, we measured the acrolein-lysine adduct level after 5mg/kg of
hydralazine injection. Hydralazine was injected two times before collecting spinal
cord (right after SCI within 5 mins and 2 hours before euthanizing). The data results
showed that the level of acrolein-lysine adduct was significantly decreased from
30.35+5.34 to 8.94+7.44 in moderate SCI rats and from 43.45+4.34 to 22.45+3.56 in
severe SCI rats. For the band densities’ analysis, Image J was used. N=6 in all groups
and p<0.05 in both moderate and severe groups between hydralazine treatment and
SCI only group.
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Figure 11. Urine 3-HPMA Level Reduction by Hydralazine
To determine effect of hydralazine, urine 3-HPMA was detected from SCI rat for
seven days. Urine was collected every 24 hours for seven days and 5mg/kg of
hydralazine was injected daily. 3-HPMA level was significantly decreased 1 day after
hydralazine injection. N=4 in each group (כ: P < 0.05 when compared to control; #: P
< 0.05 when compared to SCI only (Day 1); ANOVA)
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Hydralazine significantly reduces tissue damage after SCI
We measured the cyst area to determine whether the hydralazine could reduce
the neurological damage after SCI. To quantify the area of cyst, we took an average
two adjacent longitudinal sections at the spinal cord mid-line and stained by luxol fast
blue method (Figure 12). There was no cyst area in control group, however, cyst
covered about 37.99% of the tissue on SCI group. When we treated with hydralazine,
the cyst area was significantly decreased (from 37.99% to 11.39%). This data
demonstrated that acrolein scavenger hydralazine could reduce area of cyst formation
after SCI.
Hydralazine improves locomotor function recovery in rat SCI
The locomotor function recovery was assessed by using BBB scale one day
after SCI and once a week for four weeks (Figure 13). As a base line, BBB score in
whole groups showed 21 points. However, one day after SCI, all animals scored 0
which indicated no movement. For the treatment group, 5mg/kg of hydralazine was
injected every day for 14 days. The BBB score in hydralazine injection group was
significantly increased compared to SCI only group starting at seven days after
hydralazine injection. Significant differences BBB score were maintained until 4
weeks. Specifically, the BBB score in SCI with hydralazine treatment group was
16.12 ± 1.03, and BBB score in SIC only group showed 12.44 ± 1.17 which was
significantly lower than that of hydralazine treatment group (p<0.05). The BBB score
in Sham injury group was 18.45±1.05 one day after SCI, but one week after SCI, we
observed normal locomotor function (BBB score 21). During the test periods, there
was no motor deficit behavior in control group.
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Figure 12. The Effect of Hydralazine on Cyst Area Reduction after SCI
Cyst area was quantified 4 weeks after SCI using saline injected uninjured spinal cord,
SCI only spinal cord, and SCI with hydralazine treatment group. A-C) Luxol fast blue
staining showed the size of cyst area in the spinal cord. (A) uninjured saline injection
site, (B) SCI only, and (C) SCI with hydralazine injection spinal cord. The cyste area
in hydralazine treatment group was significantly smaller than SCI only group
(11.39±5.44% vs. 37.99±4.32%, p < 0.01, student t test). N=4 in each group.
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Figure 13. Systemic Application of Hydralazine Increased Motor Function
Recovery after SCI
SCI animals’ locomotor function was assessed by BBB score. Before SCI surgery, all
group showed normal gaits (21 points). One day after SCI, BBB score in all groups
were 0 except sham injury group. Acrolein scavenger hydralazine (5mg/kg) was
injected for 14 days daily. One week after SCI, the BBB score in hydralazine
treatment group was statistically higher than SCI only group and this trend kept
maintained until 4 weeks. Specifically, the BBB score in hydralazine treatment group
was 16.12 ± 1.03 and that in SCI only was 12.44 ± 1.17 (p<0.05). There was no
abnormal motor function in control group during the test period. N=10-13 in each
group.
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Hydralazine attenuated acute neuropathic pain behavior following SCI
In addition to the functional benefits of hydralazine on motor function
recovery, we also tested the effect of acrolein scavenger hydralazine on sensory
dysfunction in SCI. Specifically, we investigated whether hydralazine could attenuate
the neuropathic pain behavior through reduction in acrolein level after SCI. For this,
again, 5mg/kg of hydralazine was injected systemically for two weeks every day.
Neuropathic pain behavior, allodynia, was assessed by using von Frey filaments. SCI
animals’ mechanical threshold was measured one day before SCI as a base line, and
started at 2 weeks after SCI (Figure 14). Normally, mechanical allodynia test could be
started when the SCI animals could support their body weight via their hindlimb and
figure 14 showed that two week after SCI, mechanical allodynia was well established.
Based on 50% up-down method, the maximum threshold is 15.0g and minimum
threshold is 0.25g (Chaplan et al., 1994). The base lines of control, sham, SCI only,
and SCI with hydralazine treatment were 14.02 ± 0.8 g, 14.65 ± 0.3 g, 14.3 ± 0.7 g
and 13.92 ±1.0 g, respectively. During the test periods, there were no changes of
mechanical threshold in control and sham injury groups. However, mechanical
threshold in SCI only group was significantly lower than that in SCI with hydralazine
treatment groups at two weeks after SCI. In addition, neuropathic pain behavior was
significantly decreased in SCI with hydralazine treatment group during test period
compared to SCI only group. Specifically, mechanical threshold in SCI only was 8.1
± 1.2 g at two weeks after SCI, which was significantly higher than that in SCI with
treatment group, which was 3.71 ± 0.28 g. We could check similar mechanical
allodynia reductions in hydralazine treatment group during the test. Basically, the low
mechanical threshold means less sensitive to mechanical stimulus. So, this data
demonstrated that acrolein scavenger hydralazine could attenuate the neuropathic
pain allodynia through removing acrolein levels after SCI.
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Figure 14. Hydralazine Alleviated Mechanical Threshold after SCI
Systemic application of hydralazine alleviated neuropathic pain allodynia after SCI.
No neuropathic pain behaviors were observed in control and sham. However,
mechanical threshold in SCI only group was significantly lower than that in sham
group during the test period. Mechanical threshold in hydralazine treatment was
significantly higher than that in SCI only. This data showed that acrolein scavenger
hydralazine can attenuate neuropathic pain after SCI. # p<0.05, ## p<0.01 for
comparison between sham and SCI. * p<0.05, ** p<0.01 for comparison between
SCI+HZ and SCI. Control: N=10, SCI: N=13, SCI+HZ: N=13, Sham: N=6
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Acrolein micro-injection into the spinal cord resulted in neurological
motor function deficits and tissue damage
Next, we investigated whether the acorlein itself could induce the neurological
deficits such as motor dysfunction and neural tissue damage without traumatic injury.
For this, we injected a certain amount of acrolein into the animal’s right side of spinal
cord, and the same amount of saline was injected into the animal’s left side of spinal
cord directly (Figure 15). For the motor function evaluation, we performed BBB
locomotor test every 2 days for 14 days on each right and left hind limb. As shown in
figure 15B, BBB score, the motor function of contralateral side of acrolein injection
side was significantly lower than saline injection site, which was persistent during the
test period. This data showed that acrolein could produce motor function deficit.
In addition, acrolein alone can produce the neuronal damage on tissue. The
eosinophilic lesion area was surrounded by notable glial scar tissue with a number of
small nucleus cells. However, there was no glial scar formation on saline injection
site of spinal cord.
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Figure 15. Acrolein can Induce Neurological Deficits without Mechanical Injury
A) Acrolein and saline injection site into the spinal cord and the tissue section plan
for histology in (C). B) Micro-injected acrolein into the spinal cord could induce the
motor function deficits. Motor function was evaluated via BBB score, which was
significantly lower in acrolein injection site compared to that of saline injection site.
This trend lasted for 2 weeks. The values are mean±SEM.  ככp < 0.01 for comparison
between right side (acrolein-injected) and left side (saline injected), Student’s t-test.
N=6 in each group. C) H and E staining was used for histological analysis. There was
no morphological in saline injection site, while there was massive glial scar formation
in acrolein injection site. The inset indicated the enlarged acrolein injected area which
showed the detailed cellular damage by acrolein. Scale bar in C is 1 mm.
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2.4

Discussion
In this current study, we have demonstrated that the acrolein level was

significantly increased in contusion rat SCI model and elevated acrolein could be
decreased via acrolein scavenger hydralazine treatment. In addition to removing
acrolein, systemic application of hydralazine also could lead to a decrease in the
tissue damage, locomotor dysfunction, and neuropathic pain behaviors. Furthermore,
acrolein itself could result in neurological damage and motor function deficits without
any mechanical traumatic injury, which were very similar to the SCI-induced
neurological disorders such as tissue damage and motor neuron malfunction. These
data were supported by many of previous studies that acrolein scavenger hydralazine
could reduce acrolein-mediated cellular death via in vitro study (Shi and Blight, 1996;
Liu-Snyder et al., 2006b; Hamann et al., 2008b; Hamann et al., 2008a). Therefore,
current study demonstrated that acrolein plays an important role in the pathogenesis
of spinal cord mechanical injury.
This study has showed that acrolein level increased in contused spinal cord
injury rat model. This is the first research that proved the elevation of acrolein in the
SCI rat, even though there was previous research showing the increased acrolein level
in compression-injured spinal cord from guinea pig (Luo et al., 2005b). In addition,
we have demonstrated that acrolein level was significantly increased even two weeks
after SCI (Figure 7), while Luo et al. showed the elevated acrolein level in only one
week time period in guinea pig spinal cord. In addition, our data showed that the
maximal increase of acrolein after rat spinal cord injury was 300%, however,
increased level of acrolein in guinea pig spinal cord was 60% based on their ELISA
data . There are some different between two studies because of using different animal
species and different type of injury model (contusion vs. compression SCI model).
Also, there were differences in measuring techniques (immunoblotting vs. ELISA).
However, both of studies showed that the acorlein reached the highest level 24 hours
after SCI. So, these two studies demonstrated that the level of acrolein after SCI peak
at one day after SCI.
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By using paper spray mass spectrometer (Wang et al., 2011), we have
demonstrated that systemically injected hydralazine could reach the brain and spinal
cord within two hours. The data showed that the concentration of hydralazine in the
CNS was 20 μM in the spinal cord and 30 μM in the brain. Based on the previous
study, the minimal level of hydralazine to mitigate the acrolein-mediated neuronal
cell death was no more than 15 μM (Liu-Snyder et al., 2006b), which was within
hydralazine concentration range in the spinal cord after systemic application. Many of
studies have shown that acrolein scavenger hydralazine could attenuate neuronal
damage by using neural cell culture, and ex vivo studies using isolated spinal cord
(Liu-Snyder et al., 2006b; Hamann et al., 2008b; Hamann et al., 2008a; Hamann and
Shi, 2009). This study is the first one that demonstrates the benefits of acrolein
scavenger hydralazine as a neuroprotective agent via in vivo study. The estimated
hydralazine concentration through ex vivo or in vitro cannot be applied to the in vivo
study because of its complexity. Therefore, spray mass spectrometer data provided
the valuable aspects for hydralazine application to the in vivo study.
Our data have demonstrated that systemic application of hydralazine could
reduce acrolein level in the spinal cord following SCI by 50-70% and level of 3HPMA in urine. This data supported that the benefit of hydralazine as a
neuroprotective agent not only in vitro, but in vivo. Because we have injected
hydralazine once a day and half-life of hydralazine is only a few hours, more frequent
application of hydralazine would provide more benefits in attenuate acrolein level
follow SCI.
We have demonstrated that hydralazine also could reduce the formation of cyst
after SCI, which is a severe form of tissue damage and known as syringomyelia in
traumatic spinal cord (Nurick et al., 1970; Mudge et al., 1984; Schurch et al., 1996;
Rooney et al., 2009). This cyst area (Figure 12) would be the scar tissue such as seen
in figure 15. Therefore, the reduction of cyst area by application of hydralazine could
lead to the reduction of scar formation eventually, which acts as mechanical and
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chemical barrier for axon elongation after SCI (Giger et al.; Nguyen et al., 2009; Park
et al., 2010).
In addition to the reduction of cyst area, our data demonstrated that hydralazine
application could not only improve locomotor dysfunction (Figure 13), but attenuate
neuropathic pain mechanical allodynia after SCI (Figure 14). Neuropathic pain is the
one of major symptoms that at least 80% of SCI patients are suffering from this
neurological disease (Hulsebosch et al., 2009). Acrolein is also known as proinflammatory factor and stimulates the generation of various inflammatory
compounds which are responsible for neuropathic and inflammatory pain after SCI
(Facchinetti et al., 2007; Moretto et al., 2009). Especially, inflammation is the one of
the main reasons that contribute to onset and maintenance of neuropathic pain after
SCI (Schnell et al., 1999; Jones et al., 2005; White et al., 2005; Trivedi et al., 2006;
White et al., 2007; Donnelly and Popovich, 2008; Hulsebosch, 2008). Therefore, it is
reasonable to estimate that acroelin-mediated inflammation could result in onset of
neuropathic pain. In this sense, acrolein scavenger hydralazine could attenuate the
neuropathic pain behavior by reduction of inflammation reaction through acrolein
removing. Taken together, acrolein scavenger hydralazine could be an effective
analgesic to reduce neuropathic pain behavior, and also could be an effective
treatment to improve the motor function recovery for SCI patients.
The results of this study demonstrated that actolein could be a valuable
therapeutic target for neurological diseases and its scavenger hydralazine has a
potential value as analgesic to mitigate the neuropathic pain, and agent to improve the
motor function recovery after SCI. In spite of many of benefits of hydralazine,
hydralazine has some limitations as an acrolein scavenger for SCI patients. Basically,
hydralazine is the FDA-approved hypertensive mediation. However, hypotension
effect by hydralazine could be a life threatening side effect to especially SCI patients
because of neurogenic shock. In this sense, the other acrolein scavengers, which do
not have a hypotension effect, are needed to be studied for SCI patients. FDAapproved antidepressant phenelzine could be an alternative to hydralazine because it

52
is not a vasodilator and its half-life is much longer than that of hydralazine (Cole and
Weiner, 1960; Wood et al., 2006a). Therefore, it could provide more neuroprotective
effect to SCI patients.
Through this study, we have demonstrated that the pathological role of acrolein
in SCI and the benefits of acrolein scavenger hydralazine on sensory and motor
function abnormalities. Since crlinical trials with ROS scavengers have failed to
produce neuroprotection effect to SCI patients because of its various side effects
(Constantini and Young, 1994; Chen et al., 1996), acrolein scavenging could be a
novel and effective way to remove the oxidative stress and promote neuronal
recovery (Anderson et al., 1994; Behrmann et al., 1994; Bartholdi and Schwab, 1995;
George et al., 1995; Pereira et al., 2009). In addition, acrolein scavenging therapy also
would provide neuroprotective effect to not only SCI patients, but other neuronal
disorder patients, especially, acrolein-related neurodegenerative diseases such as
multiple sclerosis (Smith et al., 1999; Leung et al., 2011b; Shi et al., 2011),
Alzheimer’s disease (Lovell et al., 2001a; Montine et al., 2002). Therefore, acrolein
scavenging has the valuable potential to improve the quality of patients’ life.
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CHAPTER 3. ACROLEIN INVOLVEMENT IN SENSORY AND BEHAVIORAL
HYPERSENSITIVITY FOLLOWING SPINAL CORD INJURY

3.1

Introduction
Chronic neuropathic pain after traumatic SCI significantly impairs the quality of

SCI patients’. As a matter of fact, beyond paralysis, chronic neuropathic pain further
drastically impairs the quality of life for SCI victims. Despite years of research, this type
of clinical pain remains refractory to treatment. As a result, chronic neuropathic pain
could be prolonged for several decades after SCI and lead to depression and suicide
(Segatore, 1994; Cairns et al., 1996).
Based on previous study, at least 80% of SCI patients are suffering from
neuropathic pain, which is felt like burning, stabbing and electric shock like (Hulsebosch,
2008; Hulsebosch et al., 2009), and felt through the whole body, but patients describe the
location of pain is below or near the injury site level (Siddall et al., 2003). In the rodent
SCI-induced neuropathic pain model, the possible explanations for the pain at the below
injury level are, first, after SCI there could be anatomical changes. For example, the
central terminal of non-nociceptive primary afferents Aβ fibers could make new
synaptical connection with nociceptive neurons in laminae I and II. These anatomical
changes after SCI can cause the persistent hypersensitivity. Second, the changing in
excitatory interneuron after SCI. Under the neuropathic pain condition, there could be an
increased in release of excitatory neurotransmitter such as glutamate, which can bind to
its receptor NMDA. As a result, increased in calcium ion influx via NMDA receptor can
activate calcium dependent signaling pathway such as MAPK, PKC and PI3K, which can
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maintain the activation of pain transmission in dorsal horn and lead to hypersensitivity to
the stimuli. Third, there could be an interruption in the inhibitory interneurons such as
GABAergic and/or glycinergic inhibitory interneurons after neuronal damage
(disinhibition). Therefore, loss of inhibitory effect can result in perceiving normally innoxious stimuli as painful stimuli, which can contribute to the generation of neuropathic
pain after SCI. Lastly, glial cells can also lead to neuropathic pain after SCI. After SCI,
glial cells release various cytokines, which can bind to excitatory interneuron, and lead to
signal transduction down-stream to stimulate the central sensitization (Bruce et al., 2002;
Hains et al., 2003; Lu et al., 2008; You et al., 2008; Bedi et al., 2010; Wang et al., 2012).
Many of studies have demonstrated that the possible mechanisms for generation of
neuropathic pain after neurological damage, which including ionic channel imbalances,
release of pro-inflammatory factors, anatomical changes, and malfunction of neuro-glial
cells. However, the possible role of byproduct of LPO, acrolein, and acrolein-protein
adducts as important factors have been underestimated.
Acrolein, α,β-unsaturated aldehyde, is a byproduct of LPO (Esterbauer et al.,
1991b; Hamann and Shi, 2009; Shi et al., 2011), and transient receptor potential ankyrin
1 (TRPA1) channel specific agonist, which are most likely expressed on peptidergic
nociceptive sensory neuron (Bautista et al., 2006). Acrolein has been implicated in many
of neurodegenerative disease with its reactive and long half-life properties, which could
induce the vicious cycle of oxidative stress and enhance its effect (Shi et al., 2011; Wang
et al., 2011). As a specific agonist for TRPA1 channel and pro-inflammatory agent,
increase level of acrolein could lead to the generation of neuropathic and inflammatory
pain after neuronal damage (Story et al., 2003; Bautista et al., 2006; del Camino et al.,
2010). One of the previous studies showed that persistent elevated acrolein level at least
two weeks after SCI and it could result in onset of neuropathic pain allodynia after SCI
(Park et al., 2014).
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The FDA-approved hypertensive medication hydralazine has shown that its ability
to react with acrolein and acrolein-protein adduct and neutralized them (Burcham and
Pyke, 2006). Based on previous studies, acrolein scavenger hydralazine can mitigate
acrolein-medicated cellular, cytotoxicity (Hamann et al., 2008a; Hamann and Shi, 2009)
and damaged spinal cord by compression injury (Luo et al., 2005b). Although we do not
know yet the degree to which acrolein involve in SCI-induced neuropathic pain behavior,
acrolein scavenger hydralazine may provide effective therapeutic strategy for people who
are suffering from neuropathic pain after SCI through scavenging acrolein and acroleinprotein adducts. The goal of this chapter is to investigate the hypothesis that acrolein can
increase excitability of SCI-derived DRG sensory neurons, and hydralazine can attenuate
the neuropathic pain behavior via SCI-induced acrolein and acrolein-protein adducts
scavenging.
3.2

Materials and Methods
Animal
See Chapter 2
Contusion spinal cord injury rat model
See Chapter 2
Hydralazine application
See Chapter 2
Neuropathic pain mechanical allodynia test
See Chapter 2
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Acrolein micro-injection
See Chapter 2
Isolation of spinal cord
See Chapter 2
Protein immunoblotting
See Chapter 2
Neuropathic pain cold allodynia test
Cold allodynia was measured using 100% acetone-induced cooling test. Animals
were placed on the metal mesh in the transparent plastic box for at least 10 mins for
acclimation. Then, 0.05 ml of acetone was applied to the animals’ plantar paw skin from
a distance of 2 mm from paw surface. The acetone was applied 5 times to each paw skin
and took an average a withdrawal frequency. To prevent from sensitivity to cold stimulus,
we waited 5 min in between tests. The brisk withdrawal movement and/or licking and/or
biting behaviors are considered to be a positive response.
For the neuropathic pain behavioral tests, to minimize the stress to the animals, the
least stressful factor was applied first. Therefore, in this study, the order of the pain
behavioral test was mechanical allodynia von Frey filament assay and then cold allodynia
acetone-induced cold test. The tests order was maintained throughout the experimental
period for all animals. In addition, we performed two different behavioral tests at interval
of, at least, 20 min.
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RNA isolation and cDNA synthesis
For the real time PCR (RT-PCR), we collected L1-L6 DRG cells from sham and
SCI animals 1 week after SCI. Total RNA was isolated from samples using 1 ml of Trizol
reagent (Sigma-Aldrich, St. Louis, MO). Isolated RNA was extracted by chloroform and
precipitated by isopropanol. RNA concentration was determined using NanoDrop 2000c
(Thermo Scientific, DE, USA). Then, the extracted RNA was dissolved in 50ul of
RNase-free distilled water and stored at -80Ԩ deep freezer until in use. cDNA was
synthesized by iScript™ cDNA Synthesis kit manual guide (BIO-RAD,170-8890,USA)
using one microgram of total RNA from each sample.
Real-time PCR
Primers were designed for RT-PCR based on the previous study (Nozawa et al.,
2009). To recognize the trpa1 channel 5′-TCCTATACTGGAAGCAGCGA-3′, and 5′CTCCTGATTGCCATCGACT-3′;
CGGCTACCACATCCAAGGAA-3′

18S
and

was

used

as

an

internal

control

5′-GCTGGAATTACCGCGGCT-3′.

5′The

accumulation of PCR products were measured by the level of iQ™SYBR Green
Supermix (BIO-RAD, 170-8880, USA) fluorescence following manufacturer’s manual on
a 7300 Read Time PCR System (Applied Biosystems). The interested gene expression
level (trpa1) was normalized by the expression of 18s expression. Relative quantification
was calculated as X = 2 – ΔΔCt, where ΔΔCt = ΔE−ΔCt and ΔE = Ct exp – Ct18s, ΔCt =
Ct control – Ct 18s (Livak and Schmittgen, 2001). Data were then normalized to the
average of the control groups.
Dissociation of DRG cell and preparation
Based on the previous study, the L3-L6 DRG cells were dissociated acutely (Ma
and LaMotte, 2005). We collected DRG cells from sham control and SCI group 3 weeks
after SCI. These DRG cells were treated with collagenase A and collagenase D in HBSS
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for 20 min (1 mg/ml; Roche Applied Science, Indianapolis, IN), then treated by papain
(30 U/ml, Worthington Biochemical, Lakewood, NJ) in HBSS containing 0.5 mM EDTA
and cysteine at 35 °C. The cells were placed in culture media, which contains 1 mg/ml
bovine serum albumin (BSA), trypsin inhibitor (Worthington Biochemical, Lakewood,
NJ), Ham’s F-12 mixture and DMEM, 10% fetal bovine serum (FBS), penicillin and
streptomycin (100 µg/ml and 100 U/ml) and N2 (Life Technologies). The cells were
placed on coverslips which coated with poly-L lysine and laminin (BD Biosciences) and
incubated for 2-3 hours, then additional culture media was provided to the wells. Cells
were cultured for 12-15 hours at 37°C with 5% CO2.
Intracellular Ca2+ imaging
To investigate the intracellular Ca2+ imaging, DRG cells were in a balanced sterile
salt solution (BSS) [NaCl (140 mM), Hepes (10 mM), CaCl2 (2 mM), MgCl2 (1 mM),
glucose (10 mM), KCl (5 mM)] for 25 min at room temperature with Fura-2 AM (3 µM,
Molecular Probes/Invitrogen Corporation, Carlsbad, CA). After rinsing with the BBS, the
cells were placed onto the inverted microscope chamber. MetaFluor software (Molecular
Devices Corporation, Downington, PA) and digital video microfluorometry with an
intensified CCD camera coupled to a microscope were used for measuring Intracellular
calcium level. We selected the Fura-2 (340/380 nm) excitation wavelengths by a filter
changer, and a 150W xeonnon arc lamp were used for cell illumination. Before adding
acrolein, sterile solution was added to the cells, and if cell responded to buffer only, this
cell was not used for neuronal responsive counts. It there was no response to buffer alone,
250 µM of acrolein was applied into the coverslip directly. We waited for 2 min then
washed out acrolein solution, if there was no response. After washing out acrolein, 3 μM
of capsaicin was applied.
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Electrophysiology
Electrophysiology data recoding were performed 12-18 hours after cell
dissociation. DRG-contained coverslips were move to a recoding chamber which is on
the stage of an inverted microscope (Nikon Eclipse Ti, Nikon Instruments Inc., Melville,
NY). A bath solution (NaCl 120mM, KCl 3mM, CaCl2 1mM, MgCl2 1mM, Hepes
10mM, Glucose 10mM) was used for chamber perfusion, and adjusted to a pH 7.4 with
an osmolarity of 300 mosM. All electrophysiology data were obtained at room
temperature. Electrodes for intracellular recording were made from borosilicate glass
(World Precision Instruments, Sarasota, FL) and pulled on a Flaming/Brown micropipette
puller (P-98, Sutter Instruments, Novato, CA). Then, filling with 1.0 M KCl (impedance:
40-80 MΩ), electrodes were positioned by a micromanipulator (Newport Corporation,
Irvine, CA). For bridge-balance the electrode resistance, we used -0.1 nA current
injection. The small (≤ 30 µm), medium (31–45 µm) and large (≥ 45 µm) diameter
neurons were used for electrophysiological recordings with continuous current cpamp in
bridge mode using an AxoClamp-2B amplifier, stored digitally via Digidata 1322A
interface, and analyzed offline with pClamp 9 software (Axon Instruments, Union City,
CA). The neuronal cells that showing a resting membrane potential (RMP) more negative
than -45 mV were considered to be a positive data. For the isolated neuron studies, we
used a continuous recording for 1 min without any stimulus. Action potential data were
obtained by injecting current steps of 1 sec duration via the intracellular recoding
electrode with 0.1 nA increase. This was maintained until generating one or more action
potentials, or reaching 2 nA.
The current threshold, which is the minimum injected to evoke a single action
potential was assessed to investigated the effect of SCI itself. During the test, if there is
spontaneous discharge, the sensory neuron was considered as spontaneous activity. To
measure the excitability from small and medium diameter sensory neurons, 1s current
pulses were injected into the soma every 30 sec. Current was adjusted for eliciting 3-4
action potentials per current injection under baseline conditions. 250 µM of acrolein was
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added to the coverslip after three control current injections, which was continued every
30 sec. We measured the neuronal excitability by comparing the number of action
potentials per injected current before and after adding acrolein.
Statistical analysis
One-way ANOVA was used to identify the source of significant interactions at
each time point, followed by Tukey post hoc tests. For comparing only two conditions,
The Student T-test was used. Yates-corrected chi-square test was used for differences in
the incidence of neurons responding to acrolein. For the RT-PCR data analysis, un-paired
t-test was used. All statistical analyses were performed using IBM-SPSS Statistics
version 19.0 (SPSS inc., an IBM company, Chicago, IL, USA). P < 0.05 was considered
statistically significant and the averages were expressed in mean + SEM.
3.3

Results
Persistent elevation of acrolein protein level after traumatic SCI
The acrolein-lysine expression level was measured by using immunoblotting

(Figure 16). We collected about 1 cm of spinal cord tissue including damage site from
animals 1 day after and 2 weeks after SCI. Acrolein-lysine expression level in spinal cord
was significantly increased at both 1 day and 2 weeks after SCI. Specifically, the
acrolein-lysine level in 1 day after SCI was 39.43 ± 2.46 and that in 2 weeks after SCI
was 30.38 ± 2.71, while sham control group showed 9.68 ± 4.67, P < 0.001. This data
supported that acrolein-lysine adducts level was persisted at least 2 weeks after SCI,
which was significantly higher than that of control.
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TRPA1 mRNA gene expression level in the DRG after SCI
To investigate the potential effect of acrolein on generation of neuropathic pain
after SCI, we measured TRPA1 mRNA expression level via Real Time PCR (RT-PCR).
For this study, we collected L1-L6 DRG cells from sham control and SCI 1 week after
SCI (Figure 17). The data showed that TRPA1 mRNA level was significantly increased
in DRG cells (2.03±0.11 fold) compared to the sham control group in 1 week after SCI.
This data demonstrated that SCI could affect the expression level of TRPA1 channel,
which may be related to increased-acrolein level.
Increase of [Ca2+]i in DRG sensory cells by acrolein after SCI
We have demonstrated that there were increase in acrolein level in spinal cord
tissue and TRPA1 gene expression level SCI. Next, we investigated whether the
exogenous acrolein can induce the increase of intracellular calcium level in DRG cells,
which were collected from sham and SCI animals (Figure 18). The data indicated that
about 38% of DRG sensory cells from sham control responded to acrolein alone, while
about 14% of DRG cell from sham control responded to capsaicin and acrolein mixture.
However, the percentage of DRG sensory cells that responded to acrolein from SCI
groups was 58% (54/93) this was significantly higher than that in sham group (P < 0.005,
Chi-square with Yates correction). There was no change in percentage of cell that
responded to acrolein and capsaicin mixture compared to those in sham control group
(17%). In addition, there was no change in the number of cells that responded to the
capsaicin alone between sham control group (31%, 32/103) and SCI group (28%, 26/93 p
> 0.05). This data demonstrated that, after SCI, there was an increased number of DRG
sensory neurons, which are sensitive to acrolein.
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Figure 16. Elevation of Acrolein-Lysine Adduct Level after SCI
Immunodotblotting data indicated that SCI could result in the increase of acrolein-lysine
adduct level in the spinal cord both 1 day and 2 weeks after SCI. Even though the
acrolein-lysine level reached the highest points 1 day after SCI, its expression level was
persisted 2 weeks after SCI. The acrolein-lysine adduct levels were 9.68 ± 4.67, 39.43 ±
2.46, and 30.38 ± 2.71 in sham, 1 day after SCI, and 2 weeks after SCI respectively. All
value were expressed as mean ± SEM and N=6 in each group.
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Figure 17. TRPA1 Gene Expression Level in DRG Cells
Relative TRPA1 gene expression level was quantified by using RT-PCR. We collected
L1-L6 DRG cells 1 week after SCI. The interested gene level was normalized by the
expression level of internal control (18s) and compared to the cycle threshold (Ct) value
of 18s. This data indicated that there was about two folds increase in TRPA1 gene
expression level in DRG cells from SCI. Paired t-test was used for the statistical analysis
and N=4 in each group.
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Figure 18. Calcium Imaging of TRPA1 Signaling via Acrolein in DRG
A). Representative recording of a transient intracellular calcium increase in a DRG
sensory neuron dissociated from a rat, following SCI, in response to acrolein (250 µM).
The cells were loaded with Fura-2 (3 µM, Molecular Probes/Invitrogen Corporation,
Carlsbad, CA). Intracellular calcium was measured by digital video microfluorometry. B).
Calcium imaging data indicating the percentage of neurons that respond to acrolein and
capsaicin with an intracellular calcium flux in naive and SCI dissociated DRG sensory
neurons. Following acrolein application, capsaicin (TRPV1 agonist) was added to further
characterize the imaged cells as nociceptive neurons. In naïve rats, 38% of neurons
exhibited an acrolein-induced [Ca2+]i flux (n=103) where approximately one third of the
neurons also exhibited a capsaicin-induced [Ca2+]i flux (36%). In rats that were
subjected to SCI, a large percentage of neurons displayed an acrolein-induced [Ca2+]i
flux (58%, n=93). This is significantly higher than what is observed in naïve rats (∗ P <
0.005, Chi-square with Yates correction). Among the SCI rats that responded to acrolein,
29% of them also exhibited a capsaicin-induced [Ca2+]i influx. Therefore, the proportion
of capsaicin responsive cells among acrolein responsive cells is largely unchanged (P >
0.05).
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SCI can decrease the current thresholds in DRG sensory neurons
Next, we tested if SCI itself can affect the sensory neuron’s activation state. For
the Electrophysiological current clamp recordings, we used DRG cells from SCI and
sham control group (Figure 19). To get the current threshold (CT), the minimum current
was injected to evoke single action potential. The amount of current to generate single
action potential in small diameter sensory neurons from SCI group was significantly
lower than that in sham control group. It were specifically 0.9 ± 0.1 nA for sham injury
and 0.4 ± 0.1 nA for SCI (p<0.05). In addition, medium diameter from SCI group also
showed a significantly reduced amount of current that was needed to generate single
action potential compared to DRG sensory neurons from sham control group (1.1 ± 0.1
nA for sham injury vs. 0.6 ± 0.1 nA for SCI, p<0.05). However, there were no differences
in amount of current using large diameter of sensory neurons between SCI and sham
control group. Specifically, the mean current threshold for large DRG neurons for SCI
group was 2.10 ± 0.33 nA (n = 15) and 1.99 ± 0.17 nA for sham-injury animals (n =20).
This data demonstrated that SCI alone can change and increase the overall state of small
and medium diameter sensory neurons.
Increased excitability of DRG neuron after a combination of SCI and
acrolein.
Through this study, we have demonstrated that there were an increased number of
cells that responded to acrolein after SCI, and SCI alone could reduce the current
threshold to evoke single action potential in DRG sensory neuron. This time, we
investigated whether the acrolein could increase the sensitivity of single sensory neuron.
For this test, we collected DRG cells from sham control and SCI group. We tested
sensory cells’ response using sharp electrodes in current clamp mode to investigate the
degree to which acrolein could induce the excitability in single sensory neuron level.
During the study, acrolein did not induce the spontaneous activity in all tested neurons.
We could measure the increased excitability in small and medium diameter of sensory
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neurons when compared with baseline levels in DRG sensory neurons from sham control
and SCI group, after combination of repeated current injections with acrolein adding
(Figure 20). Specifically, the mean number of action potential by injecting minimum
current in sensory neuron from sham control group was 1.9 ± 0.1 APs (n=12) for control
and 4.7 ± 1.0 APs following acrolein application (n=3) (Figure 20B). However, the
average number of action potentials which can be generated minimal current injection in
sensory neuron from SCI group was 2.3 ± 0.4 APs for control (n=14) and 8.0 ± 0.9 APs
after adding acrolein (n=5) (Figure 20B). In both sham control and SCI group,
application of acrolein could increase the sensory neurons’ excitability compared to
controls (p<0.05). Furthermore, the increased excitability by acrolein in sensory neuron
was greater in SCI group compared with sham control (Figure 20B). This data indicated
that acrolein could increase the neuronal cells’ sensitivity, and acrolein-mediated
neuronal excitability was significantly enhanced in SCI group.
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Figure 19. SCI-mediated Current Threshold to Generate Action Potential
SCI alone can decrease the current threshold (CT), which is minimal current to generate
single action potential in small and medium diameter sensory neurons. Lumbar DRG
cells from sham and SCI group were used for current clamp recording. A). CT value in
small diameter sensory neuron was reduced in SCI compared to DRG cells from sham
group (A2 vs. A1). The current threshold was 0.9 ± 0.1 nA for sham injury and 0.4 ± 0.1
nA for SCI, p<0.05 (B). C) CT value in medium sensory neuron also decreased following
SCI (C1 vs. C2). Specifically, amount of injected current was 1.1 ± 0.1 nA for sham
injury and 0.6 ± 0.1 nA for SCI, p<0.05. There was no difference in CT using large
diameter of sensory neuron between sham and SCI group. The number means the number
of cells. Student’s t-test was used for the statistical analysis.
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Figure 20. Acrolein-Induced Sensory Neuron’s Excitability after SCI.
The number of action potentials by injected minimal current was measured to investigate
the acrolein-mediated excitability 2 weeks after SCI. We used small and medium
diameter of DRG cell from L3-L6 for the current clamp recordings. Using a 1 second
depolarizing current injection (ranging from 0.1 to 2.0 nA depending on the cell) every
30 seconds, two or four action potentials were generated. A) Representative recording for
application of 250 µM acrolein could increase the number of generation of action
potentials in DRG sensory neurons from SCI group. B) Acrolein application can
significantly increase the DRG neurons’ excitability in both sham control and SCI group
(n=12 for sham injury controls, and n=14 for SCI controls, ANOVA *p<0.05,).
Furthermore, the acrolein-induced sensitivity was greater in SCI compared to sham group.
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Micro-injected acrolein into the spinal cord produces neuropathic pain
behavior.
We investigated whether the acrolein alone could generate the neuropathic painlike behavior without any mechanical injury. We injected a small amount of acrolein into
the rat’s spinal cord dorsal horn directly on animal’s right side of spinal cord. For the
control, the same amount of saline was injected on the left side of spinal cord. The data
showed that micro-injected acrolein into the spinal cord could produce the mechanical
allodynia and cold allodynia on the side of injection site (Figure 21). However,
application of saline to the contralateral side did not show any specific neuropathic pain
behaviors.
Hydralazine can attenuate the neuropathic pain behavior after SCI
Next, we tested the analgesic effects of acrolein scavenger hydralazine following
SCI. 5mg/kg of hydralazine was injected via I.P injection everyday for two weeks. The
results data showed that hydralazine could significantly alleviate the mechanical and cold
allodynia compared to hydralazine non-treatment group during the experiment period
(Figure 22A and 22B). Furthermore, the acrolein-lysine adduct level was significantly
decreased in hydralazine treatment group when compared to the SCI only group (Figure
22C, p<0.05). This data demonstrated that acrolein scavenger hydralazine could attenuate
neuropathic pain behaviors after SCI via acrolein scavenging way.
Delayed application of hydralazine reduces neuropathic pain after SCI
So far, to investigate the analgesic effect of hydralazine, we have injected
hydralazine right after SCI within 5 min. However, clinically, applying medication right
after SCI is impossible. In this sense, we tested whether the delayed application of
acrolein scavenger hydralazine could attenuate neuropathic pain behaviors after SCI. So,
the same amount of hydralazine (5mg/kg) was injected 2 weeks after SCI for 5 weeks,

70
then we did mechanical and cold allodynia tests every week until 7 weeks after SCI. The
data indicated that the delayed beneficial effects of hydralazine also altered neuropathic
pain behaviors after SCI (Figure 23A). This treatment paradigm significantly attenuate
mechanical allodynia from 35 days to the end of period (p<0.05), and cold allodynia from
21 days to end of behavioral test (Figure 23B, p<0.05).
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Figure 21. Micro-injected Acrolein Produced Neuropathic Pain Behaviors
The same amount of acrolein (40nmol, 1.6 µL) and saline (1.6 µL) was injected into the
spinal cord directly, which could change the responses to mechanical and cold stimulus.
A) Mechanical threshold in acrolein injection side significantly lower than that in saline
injection side up to 10 days. B) Withdrawal frequency to 100% acetone also significantly
increase compared to saline injection side. These data showed that acrolein alone could
induce the neuropathic pain behaviors without any traumatic damage to the spinal cord.
One way ANOVA and Tukey’s test were used for statistical analysis. (∗ P < 0.05 when
compared to control group, n=4 in all groups). All data was expressed as mean + SEM.
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Figure 22. The Effect of Hydralazine on Pain Behaviors and Acrolein Level after
SCI
A and B) Daily application of hydralazine for two weeks could attenuate the SCI-induced
neuropathic pain mechanical and cold allodynia. On days from 14 to 28 after SCI, only
SCI group was sensitive to mechanical and cold stimulus compared to sham control and
SCI treatment with hydralazine (# P < 0.05 when compared to the sham injured control
and ∗ P < 0.05 when compared to SCI alone). C) Acrolein-lysine adduct level was
significantly reduced by acrolein scavenger hydralazine in one day after SCI. (n=6 in
each condition). (∗P < 0.05, ∗∗P < 0.01, ANOVA). All data (A-C) were expressed in
mean + SEM.
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Figure 23. Delayed Application of Hydralazine on Neuropathic Pain after SCI
To investigate the effect of delayed application of hydralazine, 5mg/kg of hydralazine
was injected 2 weeks after SCI for 5 weeks every day. Mechanical and cold allodynia
were assessed weekly until 49 days after SCI. A) The mechanical threshold in
hydralazine treatment group significantly lower than SCI only at 35 days after SCI until
49 days after SCI. B) Like mechanical allodynia, withdrawal frequency to acetone in
hydralazine treatment group was significantly higher than that in SCI only at 21 days
after SCI. These data showed that delayed application of hydralazine also attenuated SCIinduced hypersensitivity. (∗ P < 0.05 when compared to SCI group, n=4 for all groups).
All data were expressed as mean + SEM.
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3.4

Discussion
This study has demonstrated that SCI-injuced acrolein level could be persisted at

least two weeks at the damaged spinal cord tissue. This SCI-induced generation of
acrolein correlated with the onset of neuropathic pain mechanical and cold allodynia. In
addition, our data demonstrated that SCI could induce a reduction of current threshold to
generate action potential and an increase in the number of DRG sensory cells that
responded to acrolein. In addition, exogenously injected acrolein into the spinal cord
could produce the neuropathic pain mechanical and cold allodynia without any traumatic
mechanical damage to the spinal cord. Furthermore, application of acrolein to DRG
sensory neurons could increase the excitability of small and medium diameter of sensory
neurons following SCI. Taken together, these data strongly support that SCI-induced
acrolein plays a critical role in generation of neuropathic pain behavior as a pronociceptive factor.
Through this study, we observed increased level of acrolein after SCI may
implicate in generation of neuropathic pain by increasing sensory neurons’ excitability in
lumbar level of DRG. Because of acrolein’s nature such as diffusion cross membrane and
circulation through the system, elevated acrolein in thoracic level of spinal cord could
spread out throughout the spinal cord via subarachnoid space (Luo et al., 2005b). In
addition because of the permeability of the DRG cells, SCI-induced acrolein could
directly increase the sensitivity of sensory neurons (Devor, 1999; Abram et al., 2006;
Puljak et al., 2009).
As a pro-nociceptive factor, acrolein can induce an increase of influx of calcium
ion into the cell through TRPA1, which can also activate phospholipase C (PLC) signal
transduction (Bautista et al., 2006; Dai et al., 2007). TRPA1 channel can also promote the
pain sensitivity through other stimuli (Lennertz et al., 2012; Zhao et al., 2012; PerinMartins et al., 2013).
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There is little information about the changes in TRP channel’s expression level
after SCI. Our data showed that there was an increase in the expression level of TRPA1
gene after SCI. In this sense, TRPA1 channel could be a potential target for analgesic
medication. According to previous studies, TRPA1 antagonists could be applied as an
effective analgesic by blocking the pain transmission (Eid et al., 2008; Andre et al., 2009;
Bessac et al., 2009; Kerstein et al., 2009). However, TRPA1 antagonists for SCI-induced
neuropathic pain as analgesic remained uncertain and many of these antagonists are
needed to be studied further for clinical application.
In this sense, as an endogenous TRPA1 agonist, acrolein could be a more reliable
therapeutic target after SCI. Many of studies have shown that acrolein has been
implicated in many types of neurodegenerative diseases by damaging to the CNS,
proteins, lipids and DNA (Shi et al., 2002b; Hamann et al., 2008b; Leung et al., 2011c;
Shi et al., 2011). With acrolein’s nature and as a pro-inflammatory factor, it can
contribute to the generation of chronic neuropathic pain after SCI.
The role of acrolein in generation of neuropathic pain was assessed with acrolein
scavenger hydralazine. The data showed that systemic application of hydralazine after
SCI could reduce not only the acrolein-lysine adduct level, but also neuropathic pain
mechanical and cold allodynia. In addition, delayed application of hydralazine also
showed its analgesic effect after SCI. However, we also need to consider about the role of
hydralazine on nervous system. As the FDA approved hypertensive medication,
hydralazine promotes the increase of cGMP level in smooth muscle resulting in
relaxation of blood vessels. However, one previous study has demonstrated that cGMPPKG signaling pathway agonist could promote the sensory neuron’s excitability via in
vitro experiments (Song et al., 2006; Zheng et al., 2007). Based on these results, there is a
possibility that hydralazine application could also promote the neuropathic pain-like
behaviors such as mechanical and cold allodynia in sham control group. But, we did not
check any hydralazine-induced neuropathic pain like behavior in both hydralazine
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treatment groups. Therefore, an analgesic effect of hydralazine is correlated with
scavenging of acrolein after SCI.
There could be other TRP channels that respond to cold stimulus resulting in SCIinduced neuropathic pain other than TRPA1. TRPM8 is the sub-family of TRP channels,
which is activated by cold and cold effect-generated molecules such as menthol and icilin
(McKemy et al., 2002; Patapoutian et al., 2003; Patapoutian et al., 2009). In addition,
some of TRPA1 agonists have been shown to activate TRPM8 (Story et al., 2003).
According to the previous studies, TRPM8 has been implicated in sciatic nerve injuryinduced sensitivity to cold stimulus and tissue inflammation (Colburn et al., 2007;
Knowlton et al., 2010). However, recent studies have demonstrated that TRPM8 gene
expression level in lumbar DRG cells in significantly lower than TRPA1 gene expression
level under naïve conditions (Vandewauw et al., 2013). Furthermore, acrolein is known
as TRPA1 specific agonist which support that the analgesic effect of hydralazine
attenuates acrolein-induced neuropathic pain, which was mediated via TRPA1 not
TRPM8.
3.5

Conclusion
Our data supports that acrolein can enhance the neuronal sensitivity after SCI,

which is known as pro-nociceptive TRPA1 agonist and pro-inflammatory factor. With
evidence that elevation of acrolein level after SCI until two weeks, acrolein could be a
valuable therapeutic target for neuropathic pain. In addition, DRG neurons remain
hypersensitivity to stimuli because of persistent up-regulation of TRPA1 channel level
after SCI. In this sense, anti-acrolein strategy using hydralazine could be an effective way
to attenuate not only the initial state (acute) of neuropathic pain, but the chronic stage of
neuropathic pain following SCI.
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CHAPTER 4. THE EFFECT OF TRPA1 CHANNEL IN THE PERIPHERAL
TERMINAL AFTER SPINAL CORD INJURY

4.1

Background and Research Scope of This Study
Noxious mechanical and thermal stimuli can act on the peripheral terminals of

primary sensory afferent nerve. The conversion of mechanical, chemical and thermal
stimuli into electrical signal and signal transmission are conducted by transient receptor
potential (TRP) channels (Puljak et al., 2009). Basically, TRPs are non-selective cation
calcium ion permeable channels which comprise six transmembrane segments (S1-S6)
and ion permeable pore is located between S5-S6 (Bandell et al., 2007; Nilius et al., 2012;
Bautista et al., 2013).
The transient receptor potential ankyrin 1 (TRPA1) channel is a member of the
TRP channel family and also calcium permeable non-specific cation channel. As the only
TRPA subfamily member, TRPA1 channels are expressed in both neuronal cells such as
unmyelinated primary sensory neuron C fiber, DRG cell body and trigeminal ganglia
neurons and non-neuronal tissues such as respiratory tract, gastrointestinal tract, bladder,
and keratinocytes (Patapoutian and Macpherson, 2006; Patapoutian et al., 2009; Nilius et
al., 2012; Bautista et al., 2013). Based on channel’s ability to respond to noxious stimulus,
pain sensing channels can be divided into unimodal, which are activated by a unique
stimulus and polymodal, which are stimulated by various stimulus such as environmental
irritants, mechanical, and thermal stimuli (Dhaka et al., 2006). TRPA1 channels are
activated in a polymodal fashions. That is, TRPA1 can be activated by environmental
irritants (acrolein), thermal sensation (cold), pro-inflammatory factors (bradykinin) and
mechanical sensation (mechanical). The N-terminal and C-terminal of TRPA1 channel
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are located in the intracellular part. Specifically, the long ankyrin-repeated domain at Nterminal plays a critical role for activation of TRPA1 channel. EF-hand motif on ankyrinrepeated domain where calcium ion can bind to and activate TRPA1 channel, and cystein
and lysine neucleophilic amino acid on here, which are the targets for electrophilic
TRPA1 agonists contribute to gate the TRPA1 channel as well (Clapham et al., 2001;
Bandell et al., 2007).
According to the previous study, TRPA1 channel is known for endogenous
byproducts of oxidative stress process such as lipid peroxidation (LPO) (Andersson et al.,
2008). Byproduct of LPO after neuronal damage, acrolein is known as TRPA1 specific
agonist because of its electrophilic properties. With these properties, β-carbon of the a,βunsaturated aldehyde, acrolein can bind to nucleophilic thiol group of cystein and εanimo group of lysine residues via covalent modification. Especially, reaction between
acrolein and cystein is reversible, so acrolein can break from acrolein-cystein adduct and
react with other proteins and DNA (Hinman et al., 2006; Bandell et al., 2007; Nilius et al.,
2007; Andrade et al., 2008; Andre et al., 2009; Patapoutian et al., 2009). This covalent
modification between TRPA1 channel and electrophiles contribute to gate of TRPA1
channel and transmit pain signaling.
TRPA1 channels are also activated by non-electrophile agonists G-protein coupled
receptor indirect pathway (Bautista et al., 2005; Bautista et al., 2006). Bradykinin (BK) is
known as pro-inflammatory factor. When it binds to its receptor bradykinin 2 receptor
(B2R), it can activate phospholipase C (PLC) signaling and promote the release of
calcium ions from intracellular calcium store. Released-calcium ions can bind to EF-hand
domain which is located on N-terminal of TRPA1 activate TRPA1 channel. Acrolein is
also known as pro-inflammatory factor (Bautista et al., 2006). As an inflammatory factor,
acrolein has been shown to stimulate the release of chemokines such as monocyte
chemotactic protein-1 (MCP-1 or CCL2) (Knerlich-Lukoschus et al., 2008; KnerlichLukoschus et al., 2011). In the nervous system, MCP-1 is expressed in nociceptive
sensory neurons which are densely colocalized with TRPA1 channels (Abbadie, 2005;
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Abbadie et al., 2009). In addition, MCP-1 is released at the postsynaptic spinal dorsal
horn to promote the activity of neuronal glial cells that express MCP-1 receptor CCR2
(White et al., 2005; White et al., 2009). Based on previous study, acrolein-induced MCP1 and CCR2 activation can result in induce the neuropathic pain-like behaviors through
transactivation of TRPA1 channel (Knerlich-Lukoschus et al., 2010). In this sense, with
acrolein’s diffusive nature, stable and prolonged presence in the body, acrolein can serve
as a pro-inflammatory factor that contributes to generation of chronic neuropathic pain
after SCI by either directly or indirectly.
TRPA1 pore which is located between S5-S6 is stimulus dependent. Under the
neuropathic pain condition, it has a wide size of pore compared to normal physiological
condition, which induces the large number of calcium ion influx

(Patapoutian and

Macpherson, 2006; Bandell et al., 2007; Patapoutian et al., 2009; Nilius et al., 2012). In
chapter 3, we have demonstrated that the expression level of TRPA1 mRNA was
increased in the DRG after SCI. Based on this result, we can speculate that pain can
promote not only the TRPA1 channel expression, but also the pore size of TRPA1
channel. As we already mentioned above, TRPA1 channels are expressed on nociceptive
C fiber, specifically, peptidergic primary afferent neuron. So, when TRPA1 channels are
activated, they can activate the releases of nociceptive neurotransmitters such as
substance P and glutamate to higher order sensory neurons (Bautista et al., 2006;
Macpherson et al., 2007). In this sense, TRPA1 channels on the central ending of primary
afferent neurons in the spinal dorsal horn may play a critical role in the generation and
maintenance of pain signaling. However, there is little information about the role of
TRPA1 channels on the peripheral terminal of primary afferent sensory fiber. Therefore,
main goals of this study are to demonstrate the role and effect of TRPA1 channels in the
peripheral terminal of primary afferent nerve after SCI, and to investigate the effect of
acrolein after SCI whether it can promote the increase of sensitivity of responsiveness at
the peripheral terminal nerve. Lastly, we will investigate that the scavenging strategy
using acrolein scavenger hydralazine to check whether hydralazine treatment could
alleviate the TRPA1 expression level with various animal tissues such as DRG, dorsal
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horn of spinal cord and paw skin at 1 week and 2 weeks after SCI, and attenuate the
neuropathic pain behavior after SCI.
In this study, we assessed the involvement of acroelin in neuropathic pain after SCI
by using immunoblotting and urine 3-HPMA techniques and investigated the effect of
TRPA1 channels on peripheral terminal of a primary afferent nerve after SCI by using
RT-PCR with various tissues and time points.
4.2

Spinal Cord Injury-induced Neuropathic Pain Mechanical Allodynia
Through chapter 2 and 3, we have demonstrated that spinal cord injury could lead

to neuropathic pain behaviors. Here we again confirmed that NYU impactor induced
contusion injury at spinal cord T-10 level resulted in neuropathic pain mechanical
allodynia (figure 24). 2 weeks after SCI, the mechanical threshold in SCI group was
significantly lower than that in sham control group.
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Figure 24. Mechanical Sensory Hypersensitivity after Moderate Contusive SCI
Mechanical sensory status was determined using Von Frey filament performed before the
injury, and weekly post injury starting two weeks post SCI for up to 5 weeks. Note that
there were no difference in mechanical threshold in sham injury and SCI groups before
the injury. However, starting from 14 days post injury, the average values of the
mechanical threshold in SCI group were significantly reduced compared to sham group in
the 2-5 weeks post SCI. N=10~13 in each group. **P < 0.01. One-way ANOVA and
Tukey tests were used for statistical analysis. All values were expressed as mean ±SEM
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4.3

Changes in TRPA1 Gene Expression Level after SCI
In chapter 3, we have demonstrated that there was increased in TRPA mRNA gene

expression level in lumbar level of DRG 1 week after SCI. In this chapter, we assessed
TRPA1 gene expression level with various tissues such as DRG, dorsal horn of spinal
cord and hind limb paw skin in 1 week and 2 weeks after SCI. For the RT-PCR, we
collected L1-L6 DRG cells, dorsal horn of spinal cord including T-10 injury site, and
hind-limb paw skin from sham control group and SCI group. As the result is shown in
figure 25, the TRPA1 gene expression level was significantly increased in all tissues at 1
week and 2 weeks after SCI, however, there was no difference between 1 week and 2
weeks after SCI in dorsal horn of spinal cord, DRG, and paw skin. Specifically, TRPA1
gene expression level in spinal dorsal horn was 2.58±0.16 for 1 week and 2.57±0.43 for 2
weeks after SCI (p>0.05), in DRG (2.03±0.22 vs 1.87±0.21, p>0.05), and in paw skin
(41.45±2.99 vs 38.48±2.02, p>0.05). This data indicated that TRPA1 gene level could be
persisted at least 2 weeks after SCI.
Next, 5mg/kg of acrolein scavenger was injected for 1 week and 2 weeks after SCI
daily to investigate the benefits of hydralazine on reduction of TRPA1 channel gene
expression level in various tissues after SCI. Figure 26 showed the gene expression level
1 week after SCI in dorsal horn, DRG, and paw skin. The data indicated that systemic
application of hydralazine could attenuate gene expression level in all tissues.
Specifically, the gene expression level induction folds were reduced from 2.6±0.15 to
1.0±0.13 in dorsal horn of spinal cord, from 2.0±0.22 to 1.2±0.20 in DRG, and from
41.4±2.98 to 0.60±0.11 in hind limb paw skin. Furthermore, figure 27 showed that even 2
weeks after SCI, TRPA1 levels in SCI group were significantly higher than those in sham
control. Specifically, Gene expression level 2 weeks after SCI were significantly
increased in dorsal horn (2.57±0.45), DRG (1.27±0.22) and paw skin (38.48±2.0)
following SCI. However, acrolein hydralazine could significantly reduce the TRPA1
gene expression level dorsal horn (0.71±0.10), DRG (0.59±0.01) and paw skin
(15.25±3.12). These data demonstrated that, combined with immunoblotting and urine 3-
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HPMA results, acrolein was involved in an increase in TRPA1 gene expression level in
both peripheral and central terminal of a primary afferent nerve especially, SCI could
contribute to the increase in expression level of TRPA1 at the peripheral terminal of
primary sensory neurons. In addition, as a TRPA1 channel specific agonist, acrolein
could be a promising therapeutic target for neuropathic pain treatment after SCI.
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Figure 25. The Elevation of TRPA1 mRNA Level 1 Week and 2 Weeks after SCI
Bar graph indicates the RT-PCR relative quantification of TRPA1 mRNA examined 1
and 2 weeks post SCI at three tissue types: Dorsal horn (1 cm long including T10), DRG
(L1-L6), and paw skin (1 cm x 1cm). Gene expression was normalized by the expression
of 18 s and compared to the cycle threshold value for 18 s of tissue mRNA post SCI.
There was no difference of RT-PCR mRNA level of TRPA1 between two time points (1
week vs 2 weeks) in each tissue type. However, significant difference were detected
regarding the RT-PCR mRNA level of TRPA1 between SCI and sham group in three
tissue types at both 1 week and three week. Note near forty fold increase of TRPA1
mRNA in paw skin presented 1 and 2 weeks post SCI. ∗ P < 0.05, ∗∗∗ P < 0.005 when
compared to sham. One-way ANOVA and Tukey test. All values were expressed as
mean ± SEM.
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Figure 26. The Effect of Hydralazein on TRPA1 mRNA Level 7 Days after SCI
The suppression of TRPA1 mRNA level by acrolein scavenger hydralazine in spinal
dorsal horn (1 cm long including T10), dorsal root ganglia (DRG, L1-L6), and paw skin
assessed 7 days after SCI. Specifically, the TRPA1 mRNA levels were significantly
increased in dorsal horn, DRG, and paw skin following SCI (P < 0.05 in dorsal horn and
DRG, and P < 0.001 in paw skin group when compared to sham). However, this elevated
TRPA1 mRNA was significantly attenuated in all three tissue types with the continuous
daily IP injection of hydralazine for a week post SCI. (∗ P<0.05, ∗∗∗ P<0.005 when
compared to SCI alone, One-way ANOVA and Tukey test). N=4~8 in each group. All
values were expressed as mean ±SEM.
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Figure 27. The Effect of Hydralazein on TRPA1 mRNA Level 14 Days after SCI.
The suppression of TRPA1 mRNA level by acrolein scavenger hydralazine in spinal
dorsal horn (1 cm long including T10), dorsal root ganglia (DRG L1-L6), and paw skin
assessed 2 weeks after SCI. Specifically, the TRPA1 mRNA levels were significantly
increased 14 days post SCI in dorsal horn, DRG, and paw skin following SCI (P < 0.05 in
dorsal horn, DRG, and P < 0.001 in paw skin group when compared to sham). However,
this elevated TRPA1 mRNA was significantly attenuated in all three tissue types with the
continuous daily IP injection of hydralazine for 2 weeks post SCI. (∗ P<0.05, One-way
ANOVA and Tukey test). N=4~8 in each group. All values were expressed as mean
±SEM.
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4.4

Persistent Elevation of Acrolein Level and Onset of Neuropathic Pain
Behaviors after SCI
Through chapters 2 and 3, we have shown that there were elevated level of acrolein

and acrolein metabolite 3-HPMA level after SCI. In addition, we have demonstrated that
as a pro-nociceptive factor acrolein may correlate with onset of neuropathic pain
mechanical and cold allodynia and enhance neuronal sensitization after SCI. Furthermore,
when we treated with acrolein scavenger hydalazine, it could not only attenuate acroleinlysine adduct level and neuropathic pain mechanical and cold allodynia, but also promote
locomotor functional recovery following SCI. These data indicated that considering
neurotoxicity of acrolein, anti-acrolein therapy could be an effective treatment to alleviate
neurological deficits and enhance functional recovery for SCI patients. Here, we again
confirmed our theory by measuring acrolein level via immunoblotting, urine 3-HPMA
and neuropathic pain behavior after SCI (Figure 28).
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Figure 28. Elevation of Acroein-lysine Adducts in Spinal Cord
and 3-HPMA after SCI.
A) Bar graph depicts the elevation of acrolein-lysine adduct level in spinal cord tissue
after contusive spinal cord injury (SCI) at 1 day and 2 weeks post injury. Measurements
through dot immunoblotting indicated that SCI was associated with significant elevation
of acrolein-lysine adduct 1 day following SCI compared to sham injury group. Persistent
elevations of acrolein-lysine adduct were observed for at least 2 weeks after SCI. Top:
photograph shows a representative blot for each conditions. Bottom: Bar graph depicts
the quantification of the bands density by Image J. N=6~8 for each group. ∗ P < 0.05, ∗∗
P < 0.01. One-way ANOVA and Tukey test. B) Elevated level of 3-HPMA, an acrolein
metabolite, in urine after SCI in rats (3.5 ± 0.24 μg/mg), when compared to sham injured
group (1.9±0.21 μg/mg). Rat urine samples were collected one day after SCI to determine
3-HPMA level. N=4~6 in each group. ∗P < 0.05. unpaired t-test. All values were
expressed as mean ± SEM.
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4.5

Gene Expression Level and Behavioral Alternations by Pro-nociceptive Factor
Acrolein
In chapter 2 and 3, we have shown that acrolein alone could lead to neuronal tissue

damage, motor and sensory function deficits without any traumatic damage to spinal cord.
And also, the data indicated that SCI could result in the increase of TRPA1 mRNA
expression level in spinal dorsal horn, DRG, and paw skin 1 week and 2 weeks after SCI.
In this chapter, we investigated whether acrolein itself could promote the elevation
of TRPA1 gene expression levels in dorsal horn of spinal cord, DRG, and paw skin
without any traumatic injury. We also have tested if acrolein could promote generation of
neurological deficits such as neuropathic pain and locomotor dysfunction. Initially,
certain amount of acrolein (40nmol, 1.6 µl) was injected into the T-10 level of spinal cord
directly which was the same location as we described in chapter 2. Again, same amount
of saline was injected into the animals’ left side of spinal cord as a control. The gene
expression level was assessed using RT-PCR and tissues samples were collected 1 week
after acrolein injection. Figure 29 showed the result of relative TRPA1 mRNA gene
expression level in DRG, spinal cord dorsal horn, and paw skin. As the data indicated,
TRPA1 gene expression levels were significantly increased in all tissues 1 week after
acrolein micro-injection. Specifically, the increased gene expression levels were 83.4±5.9
folds (DRG), 56.9±8.4 folds (spinal dorsal horn) and 76.3±6.4 folds (paw skin). This data
demonstrated that acrolein alone could result in elevation of TRPA1 gene expression
level without any traumatic SCI. This data also further supported that acrolein played a
critical role in an elevation of TRPA1 gene expression level in both peripheral and central
terminal of a primary afferent nerve, and it could be the valuable therapeutic target for
SCI-induced neuropathic pain patients.
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Figure 29. The Effect of Micro-Acrolein Injection on TRPA1 mRNA Level in
Tissues
Relative TRPA1 mRNA expression level was assessed in DRG, spinal dorsal horn and
paw skin after direct injecting acrolein (40nmol, 1.6 µl) into spinal cord. For the control,
the same amount of saline was injected into the animals left side of spinal cord.
Compared to saline injection site, the gene expression levels were significantly increased
in DRG (83.4±5.9), (spinal dorsal horn) 56.9±8.4, and (paw skin) 76.3±6.4 folds. This
data indicated that acrolein could induce the gene expression level changes in the central
and peripheral terminal of primary afferent without any traumatic mechanical injury. N=4
in each group. #P<0.005 All values were expressed as mean ±SEM
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Next, we tested, again, the ability of acrolein as a pro-nociceptive factor. This
time, the experiment period has been extended from 10 days (in chapter 3) to 14 days. To
examine the effect of acrolein on neuropathic pain generation, we performed mechanical
and cold allodynia neuropathic pain tests after acrolein micro-injection every 2 days until
14 days (Figure 30). As figure 30 indicated, acrolein micro-injection into the spinal cord
promoted significant mechanical and cold hypersensitivity on the injection site, whereas
saline injection to the contralateral side led to the decreased or absence of
hypersensitivity response to mechanical and cold stimuli. Furthermore, micro-injected
acrolein-induced neuropathic pain behaviors were maintained at least 2 weeks. This data
supported that acrolein could generate the neuropathic pain mechanical and cold
allodynia without any traumatic mechanical injury to the spinal cord.
In addition to the ability of acrolein on generation of sensory abnormalities, we
tested if acrolein alone could promote the locomotor dysfunction without any mechanical
injury. For this study, the experiment period also has been extended from 10 days (in
chapter 2) to 14 days. We examined the animals’ locomotor ability of hind limb every
two days for 14 days. As shown in figure 31, we found that the micro-injection of
acrolein could produce significant locomotor malfunction on the side of acrolein injection,
while there were little changes or a decreased in BBB score until first week, but it came
back to normal BBB score (21) in 6 days after acrolein injection. This data suggested that
acrolein alone could induce the motor deficits with no traumatic injury.
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Figure 30. Micro-injected Acrolein Promoted the Mechanical and Cold Allodynia
We tested if acrolein itself could generate neuropathic pain without any traumatic injury
to the spinal cord. Using micro-pump device, 40nmol, 1.6 µl of acrolein was injected into
the right side of spinal cord and the same amount of saline was used for a control into the
left side of spinal cord at T-10 level. Micro-injected acrolein produced the significantly
changes in withdrawal frequency to cold stimuli (A) and mechanical threshold (B). N=6
in each group *P <0.05, **P<0.01 compared to control group. ANOVA and Tukey test
were used for statistical analysis. All values were expressed as mean ±SEM.
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Figure 31. The Motor Function Deficits by Micro-injected Acrolein
The changes of Basso, Beattie and Bresnahan (BBB) scores for acrolein (right, 40 nmol
dissolved in 1.6 µL)) and saline (left) injections over the course of 2 weeks. Notice the
significant reduction of the BBB score on the side of acrolein injection compared to the
contralateral or saline injected side. **p < 0.01, *P < 0.05 for comparison between right
side (acrolein injected) and left side (saline injected). One-way ANOVA then Tukey test.
n = 6 in each group. The values are mean ± SEM.
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4.6

Acrolein Increases the Peripheral Terminal Sensitivity Following SCI
Next, we have tested whether the acrolein could increase the peripheral terminal

sensitivity following SCI. For this, initially, a volume of 25 µl of acrolein (625nmol) was
injected into the intradermal plantar region of the right hind foot in sham control group
and SCI group. Therefore, there were four different groups; group 1: normal rats, group 2:
normal rats + acrolein injection, group 3: SCI rats, and group 4: SCI rats + acrolein
injection. For the acrolein injection, a 30 gauge needle attached to a Hamilton Syringe
was used (figure 32). A successful injection was considered if there was about 2 mm in
diameter of bleb formation at the injection site and needle insertion site was pressed for 1
min to prevent from leakage of acrolein solution after removal of the needle. An hour
after acrolein injection, for the mechanical hypersensitivity test, animals were placed
inside a plastic box. Mechanical threshold was measured using von Frey filaments updown method. As shown in figure 33A, peripherally injected acrolein resulted in the
neuropathic pain-like behavior in control group. In addition, acrolein-mediated
neuropathic pain behaviors were enhanced in SCI group (figure 33B). In both groups,
intradermally injected acrolein contributed to the reduction of mechanical threshold from
14.26±0.28 g to 10.65±1.22 g in control group (p<0.05), and from 5.42±0.41 g to
0.82±0.24 g in SCI group (p<0.01). However, acrolein-mediated neuropathic pain effect
was enhanced in SCI group. Specifically, the percentage of change of mechanical
threshold after acrolein injection was 25.53±10.21% in sham control group and
82.44±1.21% in SCI group (figure 33B). This data demonstrated that intradermally
injected acrolein could generate neuropathic pain-like behavior in control group and
acrolein-mediated effect was greater in SCI group compared to control group.
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Figure 32. Sites for Acrolein Injection and Mechanical Allodynia Von Frey Test
For the acrolein injection (25 µl, 625nmol), was injected using 30 gauge of needle.
Initially, the needle was inserted at the site of A and solution was injected at the site of B.
For the mechanical hypersensitivity test, von Frey filaments were applied to the site C.
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Figure 33. The Effect of Peripheral Injection of Acrolein in Control and SCI group
Peripheral paw injection of acrolein induced neuropathic pain-like behavior and its
potentiation after SCI. Mechanical sensitivity was assessed using Von Frey filament
before and after the injection of acrolein at intraplantar paw. (A) Bar graph shows that
mechanical threshold in both sham and SCI groups can be reduced significantly
following acrolein injection (∗ P < 0.05, ∗∗ P < 0.01, when compared to pre-acrolein,
One-way ANOVA then Tukey test). (B) The percent of change of mechanical threshold
in SCI following acrolein injection was significantly greater compared that in sham group
(P < 0.0001) N = 5-8 in all groups. unpaired t-test. The values are mean ± SEM
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4.7

Summary and Discussion
In this chapter, our data strongly supported that elevation of acrolein was correlated

with establishment and maintenance of neuropathic pain after SCI. In addition, RT-PCR
data showed that TRPA1 gene expression level could be persisted at least 2 weeks in the
various tissues after SCI not only at the central ending of a primary sensory nerve (spinal
dorsal horn), but also at peripheral terminal (paw skin) of a primary afferent. This data
indicated that SCI can lead to the increase the gene expression level in the nervous
system. However, when we treated SCI animals with acrolein scavenger hydralazine
everyday, it could alleviate the expression level of TRPA1 gene in dorsal horn, DRG, and
paw skin in 1 week and 2 weeks after SCI, which indicated that SCI-induced acrolein
may contribute to the up-regulation of TRPA1 gene expression level in the nervous
system after SCI. This is further supported by section 4.4. In here, micro-injected acrolein
could up-regulate the gene expression level without any mechanical injury at the spinal
cord. The data showed that the gene expression levels in acrolein injected side were
significantly higher than that in saline injection side. Animal behavioral tests on acrolein
micro-injected group also demonstrated that acrolein could lead to sensory and motor
abnormalities with no mechanical damage. Taken together, acrolein, as a TRPA1 channel
specific agonist, could be a promising therapeutic target for neuropathic pain treatment
after SCI.
Especially, out RT-PCR data indicated that increased TRPA1 gene expression level
at the peripheral terminal of primary afferent nerve may contribute to the hypersensitivity
to the stimuli after SCI. According to the previous studies (Nilius et al., 2007; Anand et
al., 2008; Andre et al., 2009), TRPA1 channels were also expressed at the keratinocytes
at the peripheral nerve. Our RT-PCR data figure 25, showed that the TRPA1 gene
expression level in paw skin was much higher than that in any other tissues at 1 week and
2 weeks after SCI (41.4±2.98 folds in skin, 2.6±0.15 folds in dorsal horn, and 2.0±0.22 in
DRG at 1 week after SCI and 38.48±2.0 folds in paw skin, 2.57±0.45 folds in dorsal horn,
and 1.27±0.22 folds in DRG at 2 weeks after SCI). This data indicated that neuropathic
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pain mechanical and cold allodynia following SCI most likely due to the up-regulation of
TRPA1 expression level in peripheral terminal of primary afferent sensory neurons. This
is also further supported by two animal behavioral in vivo tests. First of all, as shown in
figure 29, micro-injected acrolein directly into the spinal cord caused the up-regulation of
TRPA1 gene expression level at the spinal dorsal horn, DRG, and skin. In addition, it
induced neuropathic pain mechanical and cold allodynia. This acrolein-induced
hypersensitivity to the mechanical and cold stimuli may be mainly caused by upregulation of TRPA1 gene expression at the peripheral terminal of primary sensory
neurons. Secondly, data from figure 33 supported this theory. Figure 33 showed that
acrolein intradermal injection could generate the neuropathic pain-like behavior in
control animal group. However, acrolein-mediated neuropathic pain behaviors were
enhanced in SCI in case of mechanical threshold. This behavioral phenomenon may be
due to the increase of TRPA1 expression level at the peripheral ending of primary
sensory neuron after SCI as we have already seen in figure 25 and 26.
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CHAPTER 5. THE EFFECT OF PHENELZINE AS AN ALTERNATIVE TO A
HYDRALAZINE

5.1

Background and Research Scope of This Study
The majority of researches on the acrolein scavengers have used the hydralazine,

because its acrolein scavenging capacity was much greater than other well known
aldehyde scavengers such as methoxyamine, aminoguanidine, pyridoxamine, and
carnosine (Burcham et al., 2002; Burcham et al., 2004; Kaminskas et al., 2004b).
Compared to hydralazine, the other acrolein scavengers such as phenelzine have less
attention, even though it has also acrolein-scavenging capabilities (Burcham et al., 2002;
Wood et al., 2006b).
Through previous study, our in vitro experiment results have demonstrated that the
ability of phenelzine to protect against acrolein-mediated cell death was very similar to
that of hydralazine, and its protection capability seemed to increase with higher
concentration. In addition, although there was no difference statistically between
phenelzine and hydralazine, phenelzine could provide slightly better protection against
free acrolein. Furthermore, cell viability data with phenelzine and hydralazine in
uninjured cells demonstrated that phenelzine also provided the cellular protection through
scavenging free radicals, which were produced by normal cells.
Although hydralazine has benefits for acrolein scavenging, it has also some
limitations for in vivo treatment. Basically, hydralazine is the FDA-approved
hypertension medication, however, anti-hypertensive effect could be the life threatening
side effect to, especially, SCI patients, which could cause the neurogenic shock. In this
sense, although many of studies have demonstrated that the effect of phenelzine as an
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acrolein scavenger via in vitro experiment, anyone hasn’t evaluated the efficacy of
acrolein scavenger phenelzine in SCI animal model. Therefore, the goal of these
experiments is to investigate the efficacy of acrolein-scavenger phenelzine as an
althernative to hydralazine at in vivo SCI animal model.
5.2

Phenelzine Treatment Reduced 3-HPMA Production
To investigate phenelzine as an acrolein scavenger, acrolein pre-incubated with

saline (0.7 mg/kg), saline + acrolein + hydralazine (5mg/kg), and saline + acrolein +
phenelzine (5mg/kg) were injected via I.P. For the acrolein scavenging, we waited for 60
min before injecting solution to the animals and 24 hour after injection, we collected
urine from animals. For the control group, only saline was injected. As indicated in figure
34, such treatment significantly attenuated the 3-HPMA levels in urine. Specifically, the
average urine 3-HPMA levels in control, acrolein + saline, acrolein + saline +hydralazine,
and acrolein + saline + phenelzine were 2.06+0.06, 76.79±1.45, 6.84±0.23, and
5.03±0.86 μg/mg respectively. This result showed that injection of acrolein containing
acrolein scavengers such as hydralazine and phenelzine could reduce the level of 3HPMA in urine compared to the acrolein only group (p<0.001). This result clearly
indicated that the reduction of 3-HPMA was correlated with acrolein scavenging by
hydralazine and phenelzine. In addition, when we compared 3-HPMA levels in
hydralazine and phenelzine treatment group, there was significantly difference between
these groups. That is, the 3-HPMA level in phenelzine treatment group was significantly
lower than that in hydralazine treatment group (p<0.05). Therefore, capability of
phenelzine as an acrolein scavenger may be more effective than hydralazine.
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Figure 34. The Reduction of Urine 3-HPMA by Acrolein Scavengers
For the 3-HPMA urine test, we collected urine 24 hours after I.P. injection. The 3-HPMA
level in acrolein only injection group was significantly increased following injection.
However, the elevated 3-HPMA level was decreased by more than 90% (from
76.79±1.45 to 6.84±0.23, and from76.79±1.45 to 5.03±0.86 μg/mg). (# P < 0.001 when
compared to control; כ: P < 0.001 when compared to acrolein only, ANOVA). N=4-5 in
each group.
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5.3

Acrolein Scavenging by Phenelzine after SCI
To investigate the efficacy of phenelzine as an acrolein scavenger after SCI, we

performed immunoblotting to measure the endogenous acrolein-lysine adduct level, and
LC/MS/MS to detect acrolein metabolite urine 3-HPMA following SCI. First of all, we
generated moderate SCI animal models using NYU impactor by dropping its weight rod
from 25mm onto the intact spinal cord at T-10 level. Then, 5mg/kg of phenelzine was
injected via I.P right after SCI within 3 min. Phenelzine solution was injected 2 times
before euthanizing animals and 1 cm of spinal cord including T-10 level damage site was
collected for immunoblotting experiment. In this experiment, we had three groups; 1) SCI
only, 2) SCI + phenelzine (5mg/kg), and 3) SCI + hydralazine (5mg/kg). For the
comparison, the same amount of hydralazine (5mg/kg) was also injected 2 times before
collecting spinal cord tissue samples.
Based on constructed acrolein standard curve in figure 3, we detected acroleinlysine adducts levels after SCI in SCI, SCI+phenelzine, and SCI+hydralazine groups. As
figure 35 indicated, the acrolein-lysine adduct level in acrolein scavenger treatment
groups was significantly lower than that in SCI only group (p<0.005). Specifically, the
acrolein levels were 31.10 ± 4.21 in SCI only, 3.46 ± 1.98 in SCI + phenelzine injection
group, and 8.70 ± 1.45 in SCI + hydralazine injection group. Especially, acrolein level in
phenelzine injection group was statistically lower than that in hydralazine injection group
(3.46 ± 1.98 in SCI + phenelzine injection vs. 8.70 ± 1.45 in SCI + hydralazine injection,
p<0.05). This data supported that phenelzine could alleviate endogenous acrolein-lysine
adduct level following SCI and it may provide more acrolein scavenging effects.
In addition to immonoblotting, we also measured the acrolein metabolite 3-HPMA
from urine with various dosages of acrolein scavengers in 1 day after SCI. In this study,
we had 7 experiment groups; A: control, B: SCI post operative day (POD) 1, C: SCI
POD1 + hydralazein (5mg/kg), D: SCI POD1 + hydralazine (25mg/kg), E: SCI
POD1+phenelzine (5mg/kg), F: SCI POD1+phenelzine (15mg/kg), and G: SCI
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POD1+phenelzine (60mg/kg). As figure 36 indicated, 3-HPMA level in SCI POD1 (B)
was significantly higher than that in control (A) (3.51 ± 0.24 vs. 1.98 ± 0.21, p<0.05).
The 3-HPMA levels in hydralazine treatment groups (C (5mg/kg) and D (25mg/kg))
showed that there were reductions of 3-HPMA levels in group C and D compared to SCI
only group (B) (3.08 ± 0.22 in C vs. 3.51 ± 0.24 in B, p<0.05 and 2.22 ± 0.19 in D vs.
3.51 ± 0.24 in B, p<0.01). The 3-HPMA levels in phenelzine injection groups were 2.84
± 0.25 in E (phenelzine (5mg/kg)), 1.86 ± 0.13 in F (phenelzine (15mg/kg)), and 0.83 ±
0.17 in G (phenelzine (60mg/kg)). All 3-HPMA levels in these groups were statistically
lower than that in SCI POD1 group (B vs. E, p<0.05, B vs. F, p<0.01, B vs. G, p<0.005).
In this result, there was no difference between C and E also there was statistically no
difference between D and E. However, although there was no difference between D
(hydralazine 25mg/kg) and E (phenelzine 5mg/kg), the 3-HPMA level in group E was as
low as group D was. In addition, 3-HPMA level in group F (phenelzine 15mg/kg) was
significantly lower than that in group D (hydralazine 25 mg/kg) (p<0.05). Taken these
immunoblotting and 3-HPMA urine data together, phenelzine could be an effective
acrolein scavenger compared to hydralazine.
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Figure 35. Reduction of Acrolein-lysine Adduct Level by Acrolein Scavengers
Using immunoblotting, we measured the acrolein-lysine adduct levels from 1 day after
SCI animals. Acrolein level were 31.10 ± 4.21 in SCI only, 3.46 ± 1.98 in SCI +
phenelzine injection group, and 8.70 ± 1.45 in SCI + hydralazine injection group.
Especially, acrolein level in phenelzine injection group was significantly lower than that
in hydralazine injection group. N=4-6 in each group, ANOVA and Tukey tests for the
statistical analysis. #p<0.05 when compared to hydralazine injection group and *p<0.01
when compared to SCI only.

105

Figure 36. 3-HPMA Level in 1 Day after SCI with various Dosages of Acrolein
Scavengers
For the 3-HPMA measurement, we have 7 different groups. A: control, B: SCI postoperative day (POD)1, C: SCI POD1 + hydralazein (5mg/kg), D: SCI POD1 +
hydralazine (25mg/kg), E: SCI POD1+phenelzine (5mg/kg), F: SCI POD1+phenelzine
(15mg/kg), and G: SCI POD1+phenelzine (60mg/kg). All 3-HPMA levels in phenelzine
injection groups were statistically lower than that in SCI POD1 group (B vs. E, p<0.05, B
vs. F, p<0.01, B vs. G, p<0.005). In addition, 3-HPMA level in group F was significantly
lower than that in group D (p<0.05). This data indicated that phenelzine might be a better
acrolein scavenger compared to hydralazine. N= 4-6 in each group. ANOVA and Tukey
tests were used for statistical analysis. Urine from animals was collected 24 hours after
SCI.
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5.4

Analgesic Effect of Phenelzine on Neuropathic Pain after SCI
The benefit of phenelzine as an analgesic was investigated on SCI-induced

neuropathic pain animal model. Initially, we created the moderate contused-SCI animal
model by using NYU impactor. Based on 3-HPMA result, 15mg/kg of phenelzine was
administrated for 2 weeks daily via systemically. For the comparison, hydralazine
(5mg/kg) was injected for 2 weeks every day. Therefore, in this study, there were four
different groups; 1) Sham control, 2) SCI only, 3) SCI + hydralazine (5mg/kg), and 4)
SCI + phenelzine (15mg/kg). For the behavioral tests, we performed the mechanical and
cold allodynia tests. For the experimental set up, we followed the materials and methods
part in chapter 2 and chapter 3.
Figure 37 showed mechanical threshold on various groups. Initially, the base lines
were 15 grams in sham control, 14.23 ± 0.56 g in SCI only, 15g in SCI + phenelzine
injection, and 15g in SCI + hydralazine injection group. However, from 2 weeks after
treatment, mechanical threshold in acrolein-scavenger groups were significantly higher
than that in SCI only group, which were lasted until the end of experiment periods.
Specifically, mechanical threshold in phenelzine injection group was significantly higher
than that in hydralazine treatment group 2 weeks after injection (14.44 ± 0.44g vs. 7.02 ±
0.48g, p<0.005). This trends were maintained until 4 weeks (8.58 ± 0.42g vs. 6.55 ±
0.76g in 3 weeks after injecting (p<0.05), and 8.27 ± 0.43g vs. 6.40 ± 0.66g 4 weeks after
injecting (p<0.05)). During the test periods, there was no significant change in sham
control group. Also, mechanical threshold in SCI only group showed consistently
hypersensitive to mechanical stimulus during the test 2.48 ± 0.73g in 2 weeks, 2.55 ±
0.48g in 3weeks, and 2.61 ± 0.78g in 4 weeks after SCI. This data indicated that acrolein
scavenger phenelzine could attenuate the SCI-induced neuropathic pain mechanical
allodynia and its efficacy was better than hydralazine’s.
We also performed the cold allodynia test using 100% acetone. Similar to chapter 3,
we applied 100% of acetone onto the plantar surface of SCI animals 5 times per each side
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of hind limb and expressed it as withdrawal frequency to cold stimulus. Therefore, higher
frequency means that animal was sensitive to acetone-generated cold effect. As indicated
in figure 38, 2 weeks after SCI, neuropathic pain cold allodynia was well established on
SCI animal group. In addition, during the whole experiment period, the withdrawal
frequency in phenelzine and hydralaznie treatment groups was significantly lower than
that in SCI only group. Especially, in 2 weeks, the frequency in phenelzine injection
group was statistically lower than that in hydralaznie injection group (2.50 ± 0.56% vs.
27.65 ± 5.94%, p<0.005). However, there was no difference between these groups during
last of periods. This data also supported that phenelzine could alleviate the SCI-induced
neuropathic pain cold allodynia after SCI, and although benefit of phenelzine was only 2
weeks time point, phenelzine may provide better neuroprotective effects in the initial
stage of neuropathic pain on cold allodynia.
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Figure 37. Phenelzine Reduced the SCI-induced Mechanical Allodynia
15mg/kg of phenelzine was injected into the SCI animals everyday for two weeks. The
mechanical threshold was assessed by von Frey filaments up-down methods. As data
indicated, mechanical thresholds in phenelzine and hydralazine injection were
significantly higher than that in SCI only during the experiment periods. Especially,
mechanical threshold in phenelzine injection group was higher than that in hydralazine
injection group during the whole experiment periods. This data demonstrated that
phenelzine could attenuated SCI-indiced neuropathic pain mechanical allodynia and its
effect may be better than hydralazine. N=4-13 in each group, ANOVA and Tukey tests
were used for statistical analysis. **p<0.005, *p<0.05 compared to SCI +HZ, #p<0.01
compared to SCI only.
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Figure 38. Phenelzine Reduced SCI-induced Neuropathic Pain Cold Allodynia
Withdrawal frequency to 100% acetone was assessed to investigate the effect of
phenelzine on cold allodynia. For 2 weeks every day, 15mg/kg of phenelzine was
injected into the SCI animal via I.P. During the experiment periods, frequency in acrolein
scavengers treatment groups was lower than that of SCI only group. At 2 weeks after
injection, phenelzine injection group showed the less sensitivity to cold stimulus than
hydralazine injection group. This data indicated that phenelzine also could attenuate SCIinduced cold allodynia. N=4-13 in each group, ANOVA and Tukey tests were used.
**p<0.005 compared to phenelzine injection group, &p<0.001 compared to SCI only,
and #p<0.005 compared to hydralazine injection group.
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5.5

Summary and Discussion
Throughout this dissertation, we have used hydralazine as an acrolein-scavenger to

alleviate acrolein-mediated neuronal damage, motor and sensory abnormalities following
SCI. Hydralazine is the FDA-approved vasodilator. However, anti-hypertensive effect
could be a life threatening side effect to SCI patients because of neurogenic shock.
Therefore, with this information, someone might point out limitations of our studies
(using hydralazine as an acrolein scavenger for neuroprotection after SCI). However,
through the entire of these studies, the dosage of hydralazine was 5mg/kg, which was
significantly lower than the suggested upper limitation for human patients with safe
dosage, which is 7.5 mg/kg (Hamann and Shi, 2009). In addition, metabolite rate of
rodents is much faster than that of human. Therefore, even though higher dosage of
hydralazine could be metabolized very fast. This is supported by our data. In figure 36,
we have injected 25mg/kg of hydralazine into group D for 3-HPMA detection. Even
though the administered hydralazine (25mg/kg) was much higher than suggested upper
limitation, we did not see any hypotensive side effect on SCI animals. However, although
any hypotensive side effect by hydralazine has not been observed through this study, it is
important to point out some limitations of hydralazine for clinical application.
Fortunately, some research groups identified another acrolein scavenger phenezine
which could alleviate acrolein-mediated cellular toxicity (Parent et al., 2002; Kaminskas
et al., 2004b; Wood et al., 2006b). Phenelzine is a monoamine oxidase inhibitor which
has a hydrazine functional group like hydralazine (Wood et al., 2006b). Therefore,
phenelzine could be an acrolein-scavenger and, like hydralazine, it may react with
acrolein 1:1 molecular ratio. However, compared to hydralazine, phenelzine could offer
the some advantages. First, the half-life of phenelzine is much longer than that of
hydralazin. Based on previous study, the half-life of phenelzine was 11.6 hours, which
was much longer than half-life of hydralazine (30 min to 1 hour) (Reece, 1981). This
aspect is very important, since oxidative stress and acrolein production contribute to the
secondary cascade events after primary traumatic SCI, which are occurred in the hours,
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days, and weeks. Our data also supported this notation, through chapter 2, 3, and 4, we
have demonstrated that acrolein-lysine adduct level was persisted at least 2 weeks after
SCI (Due et al., 2014; Park et al., 2014). Therefore, with longer half-life of phenelzine, it
may provide additional neuroprotective effect via acrolein scavenging after SCI. Second,
phenelzine is not a vasodilator thus, it does not offer hypertensive side effect to SCI
patients. Based on our data in figure 36, we injected 60mg/kg of phenelzine into the SCI
animal and no anti-hypertensive effects were observed. In this sense, with phenelzine’s
long

half-life

and

non-hypertensive

effect,

phenelzine

may

offer

additional

neruoprotective role to the CNS following initial trauma. Lastly, phenelzine is the FDAapproved anti-depressant. Therefore, it could bring additional benefits to SCI patients
who are suffering from chronic neuropathic pain and post traumatic stress after SCI.
The benefits of phenelzine were further supported by previous in vitro data. Based
on in vitro tests, acrolein scavenging effects of phenelzin were very similar to
hydralazine’s with concentration dependent way. Acrolein-treated cell viability test with
various acrolein scavengers such as phenelzine and hydralazine indicated that the
phenelzine had an ability to protect against acrolein-mediated cell death, which was
statistically no different from hydralazine treatment group. In addition, cell viability was
also improved in uninjured cells by treating phenelzine, since it could remove the
endogenous acrolein produced by PC12 cell, and also the free radicals such as DPPH
which were produced by normal cells.
In addition to the in vitro results, the benefits of phenelzine as an acrolein
scavenger were supported by our in vivo SCI animal study. The immunoblotting and
urine 3-HPMA data results demonstrated that phenelzine could result in the reduction of
acrolein levels after SCI (Figures 35 and 36). Especially, these data showed that
phenelzine could be a better acrolein scavenger than hydralazine is, since the acroleinlysine adduct level in phenelzine group was significantly lower than that in hydralazine.
In addition, although there was no different of 3-HPMA levels between 25mg/kg of
hydralazine injection group and 5mg/kg of phenelzine injection group, 3-HPMA level in
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5 mg/kg of phenelzine injection group was as low as 25mg/kg of hydralazine injection
group was. Furthermore, the 3-HPMA level in 15mg/kg of phenelzine injection group
was significantly lower than that in 25mg/kg of hydralazine’s.
The benefits of phenelzine on sensory neurons’ abnormalities following SCI were
investigated using mechanical and cold allodynia. The mechanical allodynia data (Figure
37) indicated that phenelzine also could attenuate the hypersensitivity to mechanical
stimulus. Especially, mechanical threshold in phenelzine injection group was similar to
that in sham control, and statistically higher than hydralazine’s during the experiment
period. Withdrawal frequency to cold stimulus data (Figure 38) also demonstrated the
analgesic benefits of phenelzine after SCI. Especially, at 2 weeks after SCI, the frequency
of phenelzine injection group was lower than that of hydralazine. Taken these results
together, with its long half-life and non-hypotension effects, phenelzine could be used an
acrolein scavenger with high dosage as an alternative to hydralazine. However,
phenelzine has been implicated in a wide range of side effects such as urinary retention,
muscle tremors, food restriction, and drug interaction (Verrilli et al., 1987; Stonnington et
al., 1988; Song et al., 2010). Therefore, additional research for phenelzine should be
performed. In addition, the developing novel drug delivery system also should be
continued to improve the drug’s scavenging capability.
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CHAPTER 6. THE EFFECT OF POTASSIUM CHANNEL BLOCKER ON SCIINDUCED MOTOR DEFICIT AND NEUROPATHIC PAIN

6.1

Background and Research Scope of This Study
Traumatic SCI causes myelin damage mainly in white matter, which contribute to

expose the past potassium channels at the juxtaparanodal regions (Shi and Blight, 1996,
1997; Leung et al., 2011a). Under normal physiological condition, juxtaparanodal regions
are covered by myelin, which prevent from potassium ions leaking and allow it to
depolarize to generate action potential (Chiu and Ritchie, 1980; Haghighi et al., 1995;
Sun et al., 2010; Leung et al., 2011a). Since the type of SCI is most likely contused
and/or compressed injury (Blight, 1983; Blight and Decrescito, 1986; Hayes et al., 1993;
Kakulas, 1999), myelin damage in white matter of spinal cord leads to the potassium
efflux and causes the action potential failure. Furthermore, acrolein generation resulting
from inflammation has been known to play a critical role in demyelination after neuronal
damage (Smith et al., 1999; Gilgun-Sherki et al., 2004). In this sense, blocking the
potassium channels could be an effective way to re-generate action potential after SCI
(Waxman, 1989; Blight, 1991; Shi and Blight, 1997).
4-aminopyridine (4-AP) has been identified as a fast potassium channel blocker,
which could restore axonal conduction after SCI (Blight and Decrescito, 1986; Haghighi
et al., 1995). The effect of 4-AP as an effective potassium channel blocker was supported
by recent approval by the FDA for promoting motor dysfunction in multiple sclerosis
(MS) via restoring axonal action potential. However, there are some limitations of using
4-AP for clinical applications because of its side effects such as dizziness, nausea, and
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seizures (Stork and Hoffman, 1994; Potter et al., 1998; Pena and Tapia, 1999; Korenke et
al., 2008). In this sense, a developing an alternative potassium channel blocker to 4-AP is
required.
Our lab has been focusing on a new type of fast potassium channel blocker 4aminopyridine-3-methanol (4-AP-3-MeOH). Many of previous researches have been
shown that this compound could block potassium channels and restore axonal conduction
to similar level of normal axonal conduction in various neurodegenerative disease models
such as MS, and SCI where the myelin damage is occurred (Sun et al., 2010; Leung et al.,
2011a). Furthermore, the effective lowest concentration of 4AP-3MeOH for
mechanically injured spinal cord is between 0.01 and 0.1 μM, which is significantly
lower than that of 4-AP (between 0.1 and 1 μM) (Shi and Blight, 1997; Sun et al., 2010).
However, the effects of 4-AP and 4AP-3MeOH have not been investigated in SCI and
SCI-induced neuropathic pain animal model. Therefore, in the current study, we test
whether potassium channel blockers can enhance the SCI-induced motor function deficits,
and attenuate SCI-induced neuropathic pain.
6.2

The Effects of Potassium Channel Blockers on Neuropathic Pain
Initially, we have tested the effect of potassium channel blockers such as 4-AP and

4AP-3MeOH on SCI-induced neuropathic pain model. We generated contused-SCI
model by using NYU impactor. Two weeks after SCI, two different types of potassium
channel blockers were used for this study; 4-AP and 4AP-3MeOH injection groups.
Based on the previous study (Sun et al., 2010), since the effect of potassium channel
blockers is transient, we performed mechanical and cold allodynia tests every one hour
after injection until 6 hours, and did the same tests at 24 hours after injection. The same
amount (1mg/kg) of potassium channel blockers (4-AP and 4AP-3MeOH) was injected
via systemically.
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Figure 39 showed the mechanical threshold on the various groups. Before injection,
the mechanical thresholds in 4-AP, 4AP-3MeOH, and SCI were 2.99 ± 0.51g, 2.67 ±
0.44g, and 2.47 ± 0.14g respectively. However, from at 2 hours after injection to at 5
hours after injection, the mechanical threshold in potassium channel blocker injection
groups were significantly higher than that in SCI only group. Especially, at 3 hours after
injection, mechanical threshold in 4AP-3MeOH was 7.41 ± 0.51g, which was statistically
higher than that in 4-AP group (4.98 ± 0.61g, p<0.01). The significant differences
between 4-AP and 4AP-3MeOH were maintained by 5 hours after injection (7.23 ± 0.73g
vs. 4.45 ± 0.22g at 4 hours after injection, p<0.01, and 5.65 ± 0.44g vs. 3.51 ± 0.30g at 5
hours after injection, p<0.01). This data showed that potassium channel blocker could
attenuate neuropathic pain mechanical allodynia after SCI, and the analgesic effect of
4AP-3MeOH may be better than 4-AP’s. However, the mechanical threshold in whole
groups got closer to their initial values, which indicated that the effect of potassium
channel blocker was transient.
Withdrawal frequency to cold stimulus is shown in figure 40. The base lines of
withdrawal frequency were 52.50 ± 4.78% in 4-AP injection group, 50.00 ± 3.13% in
4AP-3MeOH injection group, and 55.50 ± 3.53% respectively, while 7.21 ± 3.21% in
uninjured control group. Very similar to mechanical allodynia, potassium channel
blockers could alleviate withdrawal frequency to 100% acetone stimulus from at 1 hour
after injection to at 4 hours after injection. In addition, the efficacy of 4AP-3MeOH, in
terms of analgesic, was further supported by this data. Specifically, at 1 hour after
injection, frequency in 4AP-3MeOH injection group was 14.51 ± 4.33%, while in 4-AP
injection group, 35.00 ± 2.89% (p<0.01). (At 2 hours after injection, 15.50 ± 2.33% vs.
27.50 ± 2.89% (p<0.01), at 3 hours after injection, 20.50 ± 4.33% vs. 32.50 ± 2.55%
(p<0.01), and at 4 hours after injection, 30.50 ± 2.21% vs. 42.50 ± 2.55% (p<0.01)).
Again, very similar to mechanical threshold, after 24 hours injection, cold allodynia
closed to base line except 4AP-3MeOH, which showed a lower frequency compared to 4AP injection group (p<0.05). This data also showed that potassium channel blockers
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could reduce SCI-induced cold allodynia, and 4AP-3MeOH might have better analgesic
capability compared to 4-AP.
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Figure 39. Potassium Channel Blockers Reduced Mechanical Allodynia after SCI
1mg/kg of 4-AP and 4AP-3MeOH were injected systemically 2 weeks after SCI. To test
the mechanical threshold, we performed von Frey filaments test. The data showed that
two different types of potassium channel blockers could reduce the mechanical threshold
from 2 hours to 5 hours after injection, but its effect was not maintained beyond 24 hours
after injection except 4AP-3MeOH injection group. N=6-8 in each group. ANOVA and
Tukey tests were used for statistical analysis. **p<0.01 compared to 4-AP injection
group, #p<0.01 compared to SCI only group, and &p<0.05 compared to SCI only group.
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Figure 40. Potassium Channel Blockers Reduced Cold Allodynia after SCI
To investigate the effect of potassium channel blockers on cold allodynia after SCI, we
applied 100% acetone onto the animals’ hind limb plantar surface. Very similar to
mechanical threshold, potassium channel blockers reduced the withdrawal frequency to
acetone during some time points (from at 1 hour to at 4 hours after injection). Still, 24
hours after injection, 4AP-3MeOH injection group showed less sensitivity to cold
stimulus compared to 4-AP injection group. N=6-8 in each group, ANOVA and Tukey
tests were used for analysis. *p<0.05, **p<0.01 compared to 4-AP injection group,
#p<0.01 compared to SCI only group.
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6.3

The Effect of Potassium Channel Blockers on Motor Function Deficits
To investigate the effect of potassium channel blockers on motor function recovery

after SCI, we administered 2 different dosages of 4AP-3MeOH (1mg/kg and 5mg/kg) and
1mg/kg of 4-AP 2 weeks after SCI. Then, 30min after injection, we performed the
rotarod tests. Rotarod test is commonly used for investigation of motor function
coordination to evaluate the effect of medication on neurogenerative diseases. Previous
study showed that gradually increased rotation speed resulted in the greater sensitivity of
the test (Jones and Roberts, 1968). Therefore, the rotation speed was gradually increased
by 3 rotations per minute (RPM) every 10 s until it reached 30 RPM and 180 s. Before
SCI, all the animals have passed this training, and we did not use the animals that did not
pass the training. When the animals completely fall off from the device, or spin around
twice on the device, we stopped the test and recorded the RPM and time on the rotarod.
These values indicated the animal’s capability of remaining on the spinning rod and
motor function recovery by injected medication.
Figure 41 showed the time on rotarod of 5 different groups; normal control (A),
SCI only (B), 5mg/kg of 4AP-3MeOH (C), 1mg/kg of 4AP-3MeOH (D), and 1mg/kg of
4-AP (E). There were no significant differences between SCI only and 1mg/kg of 4-AP
and 4AP-3MeOH groups (47.30 ± 3.69 sec. in SCI, 46.33 ± 2.01 sec. in 1mg/kg of 4AP3MeOH, and 45.55 ± 2.84 sec. in 1mg/kg of 4-AP). However, when we treated 5mg/kg
of 4AP-3MeOH, the time on rotarod was significantly longer than any other groups. We
did not investigate the effect of 5mg/kg of 4-AP on motor function recovery, since the
animals showed the seizure-like activity after injection. We also checked the rotation per
minutes (RPM) at the same time. As figure 42 indicated, there were no differences
between potassium channel blocker injection groups and SCI only group. Specifically,
the RPM in SCI only group was 9.68 ± 0.51 RPM, 9.58 ± 0.48 RPM in 1mg/kg of 4AP3MeOH, and 9.47 ± 0.39 RPM in 1mg/kg of 4-AP. However, the RPM in 5mg/kg of
4AP-3MeOH showed 9.58 ± 0.48 RPM, which was statistically different compared to
other groups. This rotarod data demonstrated that 5mg/kg of 4AP-3MeOH could promote
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the motor function after SCI, and high level of 4AP-3MeOH could be used safely
compared to 4-AP.
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Figure 41. The Effect of Potassium Channel Blocker on Motor Deficit after SCI
To assess the effect of potassium channel blockers on motor function, two differences
dosages of 4AP-3MeOH (1mg/kg and 5mg/kg), and 1mg/kg of 4-AP were injected
systemically (A: normal control, B: SCI only, C: 4AP-3MeOH (5mg/kg), D: 4AP3MeOH (1mg/kg), and E: 4-AP (1mg/kg)). The time on device in 5mg/kg of 4AP3MeOH was longer than any other groups. This data showed the high level of 4AP3MeOH could promote motor function after SCI. N=6-8 in each group. ANOVA and
Tukey tests were used for statistical analysis.*p<0.05
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Figure 42. Potassium Channel Blockers Promoted the Motor Recovery after SCI.
The animals’ motor function recovery after SCI was assessed by measuring the rotation
per minute on the rotarod (A: normal control, B: SCI only, C: 4AP-3MeOH (5mg/kg), D:
4AP-3MeOH (1mg/kg), and E: 4-AP (1mg/kg)). Similar to time on the rotarod, RPM in
5mg/kg of 4AP-3MeOH was higher than any other groups. N= 6-8 in each group,
ANOVA and Tukey tests were used for the statistical analysis, *p<0.05
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6.4

Summary and Discussion
Through this study, we have demonstrated that potassium channels blockers could

attenuate SCI-induced neuropathic pain behaviors (figures 39 and 40). Especially, in
terms of analgesic, the effect of 4AP-3MeOH was better than that of 4-AP. In addition,
although there were no difference between SCI only and treatment groups under the same
dosage of potassium channel blockers, higher dosage of 4AP-3MeOH (5mg/kg) was
effective to improve the motor function after SCI (figures 41 and 42). These behavior
tests demonstrated that potassium channel blockers could not only attenuate neuropathic
pain behaviors, but promote motor function recovery after SCI. This notion is further
supported by previous studies (Van Diemen et al., 1993; Wu et al., 2009). Furthermore,
this data showed that the efficacy and therapeutic value of 4AP-3MeOH. Even though we
did not present the data, 5mg/kg of 4AP-3MeOH also led to attenuation of neuropathic
pain mechanical and cold allodynia, and its efficacy was better than 1mg/kg of 4AP3MeOH’s. It was unable to test with 5mg/kg of 4-AP, since the animals showed the
seizure-like activity after injection, but this action went away in 2 hours after injection
because of the transient property of potassium channel blocks (Sun et al., 2010).
Furthermore, high dosage of 4AP-3MeOH (5mg/kg) also led to better results compared to
1mg/kg of 4AP-3MeOH and 4-AP. These data supported that 4AP-3MeOH could be used
as an effective potassium channel blocker with high dosage.
Two major differences between 4AP-3MeOH and 4-AP led to different results in
this experiment. First of all, the effective lowest concentration of 4AP-3MeOH (between
0.01 and 0.1 μM) to recover axonal action potential is significantly lower than that of 4AP (between 0.1 and 1 μM) (Shi and Blight, 1997; Sun et al., 2010). Secondly, based on
the ex vivo studies, when they treated with 4AP-3MeOH, axon can restore its action
potentials, which was similar to axons’ action potentials way under normal condition
(Jensen and Shi, 2003; Sun et al., 2010). In addition, 4AP-3MeOH can also significantly
enhance axonal action potential conduction in EAE mouse (Leung et al., 2011a). Based
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on these mechanisms, high dosage of 4AP-3MeOH may induce the motor function
recovery after SCI.
The hyperexcitability of primary afferent neuron after SCI results in neuropathic
pain allodynia. Although many of voltage-gated channels are implicated in transmission
of noxious stimuli to higher order of neuron and hyperexcitability, potassium channels
play an important role in transmission of pain information by regulating membrane
potential and generating action potential. In addition, neuronal damage leads to the
opening of potassium channels, which results in hyperpolarization of cell membrane
(Ficker and Heinemann, 1992; Wu and Saggau, 1997; Takeda et al., 2011). Therefore,
potassium channels have been focused on as a therapeutic target for neuropathic pain
treatment after neuronal damage. This notion is well supported by our data (figures 39
and 40). These data indicated that potassium channel blockers could attenuate
neuropathic pain mechanical and cold allodynia following SCI. Specifically, analgesic
effect of 4AP-3MeOH was better than that of 4-AP. Taken together, based on these data
using SCI-induced neuropathic pain animal model, potassium channel blockers can not
only alleviate neuropathic pain, but promote motor function recovery following SCI.
Especially, 4AP-3MeOH may be an effective potassium channel blocker as an alternative
to 4-AP in enhancing the sensory and motor dysfunction recovery after neuronal damage.
However, the working mechanisms of potassium channel blockers on the sensory neuron
for neuropathic pain, and on the motor neuron for motor function deficits after SCI are
further studied.
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CHAPTER 7. SUMMARY AND CONCLUSION

Traumatic spinal cord injury (SCI) induces motor and sensory dysfunction,
bladder reflexive dysfunction, urinary tract infection, renal malfunction, loss of
respiratory function, loss of sexual function, and pneumonia. Beyond these SCI-induced
malfunctions, neuropathic pain after SCI has significant negative effects on patients’
quality of life. In spite of research to improve and recover functional deficits after SCI,
insufficient therapeutic targets lead to a frustrating condition to treat. Recently,
antioxidants have attracted researchers’ attention to alleviate the SCI-induced
malfunctions. However, recent clinical trials using these medications have failed to
improve functional recovery after SCI. Despite of failing the clinical trials, this study
indicated that attenuating oxidative stress by targeting a neurotoxin, acrolein, could be an
effective way to improve the SCI-induced dysfunctions.
As the strongest electrophile and the most reactive aldehydes, acrolein has been
implicated in various neurodegenerative diseases (Hensley et al., 2000; Vincent et al.,
2002; Naoi et al., 2005; Liu-Snyder et al., 2006b; Schwartz et al., 2008). Acrolein can
originate through exogenously through environmental sources such as air pollution and
cigarette smoke, and endogenously through the breakdown of carbohydrates and amino
acids (Witz, 1989; Ghilarducci and Tjeerdema, 1995; Hamann et al., 2008b). In addition
to its high reactivity, the half-life of acrolein is much longer than that of the other ROS.
Acrolein can bind to protein and DNA, forming acrolein-protein adducts, which have
half-lives that are even longer than that of free acrolein. Furthermore, acrolein can bind to
endogenous anti-oxidant GSH and react with it much faster than other types of oxidative
stress-inducing molecules. With these unique properties, acrolein can induce the vicious
cycle of oxidative stress and amplify its effects after SCI.
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Because acrolein plays an important role in pathogenesis after traumatic SCI, we
have focused on acrolein scavenging as the most important means of intervention to
further degeneration after SCI. The FDA-approved hypertensive medication hydralazine
has shown its acrolein-scavenging effect with the hydrazine functional group (Burcham
et al., 2000; Burcham et al., 2002; Burcham et al., 2004). In addition, because hydralazine
can react with free acrolein and acrolein-protein adducts in an equimolar manner,
equimolar concentration of hydralazine can neutralize acrolein entirely (Burcham et al.,
2002; Burcham et al., 2004; Hamann et al., 2008a; Hamann and Shi, 2009). Many
previous studies have showed acrolein-scavenging effects of hydralazine via in vitro tests
(Liu and Wood; Burcham and Pyke, 2006; Liu-Snyder et al., 2006b). However, to our
knowledge, this is the first study that hydralazine has been shown to reduce the acrolein
levels and acrolein-induced neuropathic pain through in vivo animal SCI models.
The main goals of chapter 2 were to ascertain the pathological role of acrolein in
the CNS, and the effects of acrolein scavenging via hydralazine in an in vivo SCI animal
model. Therefore, we hypothesized, first, the level of acrolein would depend on the SCI
severity, second, suppressing acrolein would reduce the neuronal damage and promote
functional recovery, and third, acrolein itself would generate the neurological deficits.
Figures 7 indicated that the elevations of acrolein levels were correlated with SCI
severity. Specifically, the elevated level of acrolein persisted for at least two weeks after
both moderate and severe SCI groups. This was further supported by urine 3-HPMA
results (Figure 8). With a recently developed technique, LC/MS/MS, we measured the
concentration of the acrolein metabolite, 3-HPMA, in animals’ urine samples, of which
levels were also correlated with SCI severity. Before testing the benefits of acrolein
scavenging by hydralazine, we investigated whether it could reach the therapeutic level
within the CNS. Figure 9 showed that systemically injected hydralazine was detected in
concentrations higher than the minimal level needed to reduce acrolein-mediated damage.
With this information, we injected 5 mg/kg of hydralazine after SCI, and figures 10 and
11 showed that hydralazine could reduce the acrolein level. In addition to reducing
acrolein level after SCI, we also studied if hydralazine treatment could not only reduce
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the neuronal tissue damage, but also improve locomotor functional recovery after SCI
(Figures 12 and 13). These results may support that elevated acrolein after SCI lead to
neuronal tissue damage and motor dysfunction, and by scavenging acrolein through
hydralazine, we can attenuate the generation of cysts formation and malfunction of motor
neuron. This notion is again supported by figure 15. In this data, micro-injected acrolein
into the spinal cord induced the neuronal tissue damage and motor function deficits
without any traumatic injury. Through this study, we showed that, first, acrolein level is
correlated with SCI severity, second, systemic application of hydralazine can reduce
acrolein levels, neuronal damage, and promote motor function recovery, and third,
considering the role of acrolein after SCI, anti-acrolein therapy could be an effective
treatment to improve motor dysfunction and neuronal damage.
As a TRPA1 channel specific agonist and an inflammatory factor, acrolein plays
an important role in neuropathic pain pathogenesis after SCI. In chapter 2, figure 14,
showed that persistent acrolein level elevation was correlated with the onset and
establishment of neuropathic pain after SCI. In addition to increased levels of acrolein for
two weeks after SCI (figure 16), we demonstrated that the TRPA1 gene expression level
was up-regulated in various tissues such as dorsal horn of spinal cord, DRGs, and hindlimb paw skin one week and two weeks after SCI (figures 17 and 25). In addition, figures
14 and 22 showed that there was an increase in sensitivity in mechanical and cold stimuli
after SCI, furthermore, micro-injected acrolein resulted in neuropathic pain-like
mechanical and cold allodynia behaviors without any traumatic injury to the spinal cord
(figures 21 and 30). Acrolein-induced neuropathic pain generation was further supported
by up-regulation of gene expression level of TRPA1 (figure 29). However, as figures 26
and 27 indicated, hydralazine could down-regulate the TRPA1 gene expression level one
and two weeks after SCI in various tissues such as dorsal horn, DRG and paw skin.
Therefore, the DRG neurons may remain hypersensitive to its effects because of acroleinmediated persistent up-regulation of TRPA1 after SCI.
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Electrophysiological data demonstrated the effects of acrolein and SCI on cellular
hypersensitivity. As figure 18 indicated, acrolein could increase the intracellular calcium
levels after SCI and there was an increased in number of cells that responded to acrolein
after SCI. Furthermore, SCI alone could increase the excitability of nociceptors (small
and medium diameter of sensory neurons). In figure 19, we investigated the magnitude of
current thresholds to generate the single action potentials, and the data showed that SCI
could decrease the current threshold on sensory neurons. In addition, acrolein could
increase the number of action potentials on sham and SCI groups (figure 20) and
acrolein-mediated cellular excitability was enhanced after SCI. This notion is also
supported by figure 33. Intradermally injected acrolein could increase the mechanical
sensitivity to von Frey filaments in the sham control group, but acrolein-mediated
mechanical sensitivity was enhanced in SCI group.
Taken together, these data showed that acrolein could increase neuronal
sensitization, and its effect could be enhanced after SCI. In addition, considering the
persisted elevation of acrolein for two weeks and the onset of neuropathic pain after SCI,
acrolein could be a valuable therapeutic target for neuropathic pain. Therefore,
scavenging acrolein by hydralazine may be an effective way to reduce not only acute
neuropathic pain, but also chronic stages of neuropathic pain after SCI (figure 23).
With the anti-hypertensive property of hydralazine, it has number of limitations
for the SCI patients. The major drawback of hydralazine is hypotensive effect to SCI
patients, which could be a life threatening side effect because it could lead to neurogenic
shock. In addition, with its short half-life, it has to be administrated more frequently for
the neuro-protection. Recently, a monoamine oxidase inhibitor, phenelzine, was
identified as a possible acrolein scavenger. Since it has a hydrazine functional group like
hydralazine, it is reasonable to anticipate that it may react with acrolein 1:1 molecular
ratio. However, Reece and colleagues showed that the half-life of phenelzine (11.6 hours)
was significantly longer than that of hydralazine (Reece, 1981). Normally, secondary
cascade events including oxidative stress and acrolein-mediated damage to the spinal
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cord after primary injury were observed in the hours to days after injury. Therefore,
phenelzine’s long half-life property may inhibit acrolein-mediated additional damage
after primary injury. Furthermore, as the FDA-approved anti-depressant and nonhypertensive medication, phenelzine could be used with a higher dosage without severe
side effects (figure 36), and provide additional neuroprotective role for the treatment of
SCI-induced neuropathic pain behaviors (figures 37 and 38).
Based on previous studies, most SCIs are contused and/or compressed injury,
which causes myelin damage mainly in white matter leading to exposure of potassium
channels at the juxtaparanodal regions (Blight, 1983; Blight and Decrescito, 1986; Hayes
et al., 1993; Leung et al., 2011a). Efflux of potassium ions results in slowing or the
complete blocking of axonal conduction. Potassium channels play an important role in
transmission of noxious stimuli to the higher order of neuron by regulating membrane
potential and generating action potential. Therefore, many of researchers have focused on
potassium channels as a potential therapeutic target for neuropathic pain after neuronal
damage. So, initially, we tested if potassium channel blockers (4-AP and 4AP-3MeOH)
could attenuate neuropathic pain mechanical and cold allodynia after SCI. As figures 39
and 40 indicated, both potassium channel blockers could reduce neuropathic pain
behaviors, but the analgesic effect of 4AP-3MeOH was better compared to 4AP. We also
checked the benefits of potassium channel blockers on the motor function deficits after
SCI. Even though 1mg/kg of 4AP and 4AP-3MeOH did not show any effect on motor
function recovery, a higher dosage of 5 mg/kg of 4AP-3MeOH did indeed show motor
function improvement after SCI (figures 41 and 42). Taken together, potassium channel
blockers could not only attenuate the neuropathic pain behavior, but also improve the
motor function recovery after SCI. However, as we have already mentioned above,
5mg/kg of 4-AP induced the seizure-like behavior on animals, even though this activity
did not last more than 2 hours because of its transient property. So, when we consider the
efficacy and safety, 4AP-3MeOH would provide additional advantages to improve motor
and sensory dysfunctions. For the future, we need to investigate various factors that could
affect the efficacy and potency of potassium channel blockers for neurodegenerative
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disease patients. In addition, we also need to investigate the working mechanisms of
potassium channel blockers to reduce the side effects of these medications.
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CHAPTER 8. FUTURE STUDIES
We have demonstrated the potential and pathophysiological values of acrolein as
a therapeutic target for SCI-induced neuropathic pain. Our data supported that acrolein
scavengers may be a novel analgesic to intervene neuropathic pain after SCI.
In particular, the immunoblotting and urine 3-HPMA results showed that
elevation of acrolein level correlated with SCI severity and, based on the immunoblotting
result, its level could be persisted at least two weeks after SCI. In addition, systemic
application of acrolein scavengers, hydralazine and phenelzine, could decrease
accumulation of acrolein-lysine adducts and 3-HPMA levels following contusion SCI.
Although we have shown the elevation of acrolein level after SCI, it has been uncertain
what types of cells produce and accumulate acrolein after neuronal damage. Many studies
have

demonstrated

the

accumulation

of

acrolein-protein

adducts

through

immunohistochemistry (Luo et al., 2007; Ismahil et al., 2011). However, additional
studies should be performed to investigate where acrolein is produced and accumulated.
For this, we may use specific markers such as GFAP for astrocyte, DAPI for nuclei, and
MBP (myelin basic protein) for myelin. This experiment would provide additional
information about the exact location where the acrolein-protein adducts is formed. This
information could be utilized to develop the efficient acrolein scavengers as well.
Neuropathic pain data showed that, as a pro-nociceptive factor, SCI-induced
formation of acrolein correlated with the onset of neuropathic pain behaviors. This is
supported through reduction of pain behaviors by using acrolein scavengers, such as
hydralazine and phenelzine, after SCI. Furthermore, electrophysiology data indicated that
acrolein could enhance the sensory neuron’s excitability after SCI and even sensory
neuronal cells from sham control group. This phenomenon could be explained by our
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gene expression data. The data showed that the elevation and maintenance of DRG
sensory neurons’ excitability may be mediated by up-regulation of TRPA1 gene
expression level, which is also correlated with elevation of acrolein level after SCI. An
increase in TRPA1 gene expression level persisted for at least two weeks after SCI and
its levels were decreased by scavenging the SCI-induced acrolein via hydralazine.
Therefore, targeting acrolein for an analgesic effect would be a promising approach to
attenuate neuropathic pain behaviors after SCI. However, we cannot rule out the
possibility that generation of neuropathic pain by other acrolein-mediated pathways. As
we already mentioned through this study, acrolein is known as pro-inflammatory factor.
Based on previous studies, acrolein has been shown to stimulate the release of
chemokines such as monocyte chemotactic protein-1 (MCP-1 or CCL2) after SCI
(Knerlich-Lukoschus et al., 2010; Knerlich-Lukoschus et al., 2011b). In DRG, MCP-1 is
expressed in small and medium diameter of sensory neurons which are also colocalized
extensively with TRPA1 channels (Abbadie, 2005). In addition, MCP-1 is released at the
spinal dorsal horn to modulate the activity of post synaptic neurons and glial cells, which
express the MCP-1 specific receptor CCR-2 (White et al., 2009). A recent study showed
that the activation of CCR-2 by MCP-1, which was activated by acrolein, could elicit
membrane depolarization, trigger action potentials and sensitize nociceptors through the
transactivation of TRPA1 channels to generate neuropathic pain after injury (KnerlichLukoschus et al., 2010). In this sense, based on reactive nature of acrolein, coupled with
its diffusive, stable, and prolonged presence in the body, acrolein would play an
important role in an inflammation-associated pathway that leads to the chronic nature of
neuropathic pain. Therefore, the exact mechanisms and involvement of acrolein on the
immune response-mediated generation of neuropathic pain after SCI should be performed.
In line with immune system-evoked neuropathic pain, we also have to further investigate
the balance between neuropathic pain generation and neuro-inflammatory response after
injury. Under the normal physiological condition chemokines usually have positive
effects on limitation of cellular and tissue damage, and they are well controlled by a
complex network. However under neuronal damage conditions, this complex mechanism
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is also damaged, and is insufficient to control inflammation. Therefore, the inflammatory
response itself could result in a various range of chronic neuronal diseases including
neuropathic pain after SCI. So, further studies are needed to demonstrate the mechanisms
keeping a balance between neuro-inflammation and chronic neuronal diseases such as
neuropathic pain.
As a non-selective cation channel, TRPA1 channels play an important role in
transmitting pain signaling to higher order neurons. Based on our preliminary data, it is
well known that electrophilic reactive compounds such as acrolein can activate TRPA1
channel after SCI. In addition, we have demonstrated that acrolein itself could increase
the excitability of DRG sensory neuron, which is enhanced after SCI. Furthermore, our
data indicated that SCI itself could affect the overall activity of sensory neurons’
sensitivity in nociceptor neurons (c and Aδ primary afferent neurons). Together with
immunodotblotting results, our data demonstrated that formation of acrolein after SCI
was correlated with the enhancement of neuronal sensitization and elevation of TRPA1
gene expression level after SCI. As we have already mentioned in chapter 1, many of
research articles demonstrated the various mechanisms about the activation of TRPA1
channels after tissue damages. However, it is still unclear how this channel is deactivated.
Additionally, we still do not know the exact downstream biochemical signaling pathway
of the channel for subsequent activation after deactivation. Therefore, the logical next
study would be to investigate the mechanisms of TRPA1 desensitization after its
activation. Based on previous studies (Nilius et al.; Bandell et al., 2007), the binding
between acrolein and cysteine residues by Michael addition is reversible, while the other
covalent modifications are not. This property could be a key mechanism for re-activation
after deactivation of TRPA1 channel and vice versa. Therefore, initially, we should focus
on reversible reactions between the TRPA1 channel and its agonists.
As an additional approach to the TRPA1 channel desensitization study, we also
should check the effect and role of TRPA1 channel specific antagonists, such as HC-
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030031. Based on previous studies, oral administration of HC-030031 exhibited a
significant decrease in neuropathic pain-like behavior in inflammatory and neuropathic
pain animal models compared to TRPA1 antagonist non-treatment group (Eid et al.,
2008). This study showed the potential analgesic effect of TRPA1 specific antagonist on
neuropathic pain model. However, possible working mechanisms of non-electrophilic
TRPA1 channel antagonists, such as HC-030031, have not been investigated. In addition,
some research articles have shown that some electrophilic TRPA1 antagonist compounds,
such as AP-18 and A-967079, can act as both an agonists and antagonists depending on
their concentration (Garcia-Anoveros and Nagata, 2007; Chen et al., 2011). Therefore,
without exact working mechanisms of TRPA1 antagonists, the potential value of TRPA1
antagonists as therapeutic agents remains uncertain. Thus, we need to investigate the
mechanisms and optimal working concentrations of various TRPA1 specific antagonists,
either electrophilic or non-electrophilic, through in vitro tests and in vivo disease animal
models.
Although several unique properties of the TRPA1 channel make it an attractive
potential therapeutic target to treat neuropathic pain after injury, there are potential
disadvantages using TRPA1 channel for treatment. First of all, because of the wide
spread presence of TRPA1 channel in various tissues, such as bladder, skin cell, GI track,
nervous system, and respiratory track, there could be unwanted side effects when we use
TRPA1 channel-specific medications. Second, the level of correlation between human
TRPA1 and rodents TRPA1 is only 79%. Therefore, pre-clinical experimental results
with TRPA1 antagonists or agonists in rodent model would not act in the same way in the
human. In this sense, although the amino acid sequences in the N-terminal of TRPA1 or
in the EF-hand domain share some similarities, the critical amino acid such as cysteine
and lysine in the N-terminal differ between species. This difference could lead to
changing in the affinity of the agonists or antagonists to the TRPA1 channel. To
overcome this barrier, using a transgenic animal model which expresses the human
TRPA1 channel could be an effective way to reduce such discrepancies. In addition, by
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using this model, pre-clinical experiments can provide valuable information for
developing effective analgesic compounds.
One of the challenging problems of pharmacological treatment is the delivery of
compound to specific cell types. As we already mentioned above, the wide spread of
expression of TRPA1 channel in nociceptors makes it an excellent candidate for
therapeutic target. As a non-selective cation channel, TRPA1 channel’s pore size is
stimulus- and time- dependent. This feature of the TRPA1 channel can be utilized to
increase the entry of small membrane-impermeable cationic compounds into the target
sensory neuron to block the pain transmission. To accomplish this aim, we may
encapsulate therapeutic compounds in a drug delivery vehicle. By using a drug delivery
vehicle, we can not only improve a compound’s specificity for targeted cells, but prevent
undesirable side effects of TRPA1 channel.
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